I want to tell you something that might reframe years of mealtimes.

That child who covers their nose when peanut butter is opened. The one who will only eat five foods. The one who can’t sit at the lunch table when someone opens a bag of tree nuts. Parents are told this is anxiety, or sensory issues, or pickiness, or bad behavior. Pediatricians sometimes say they’ll grow out of it. Therapists are brought in. Dietary elimination trials fail.

What almost nobody tells these families is that there is a body of scientific evidence — some of it published in Nature and Science within the last two years — suggesting that a food-allergic child’s immune system may be doing something we only recently understood: it is reprogramming the brain to avoid food.

Not metaphorically. Literally. Measurably. Through specific molecules, in specific brain regions, in ways that precede visible gut inflammation and classic allergic symptoms.

This is the story of that biology. It’s also the story of what food allergy actually does to children — their growth, their social lives, their mental health — and where treatment is going. If you are a parent managing a food-allergic child, or a clinician who sees them, this is the information I think you deserve to have.

First, a few numbers most people don’t know

Food allergy affects roughly 8% of children in the United States, according to CDC data. That is approximately 6 million kids. But here’s the number that quietly gets me every time I look at it: in a 2025 survey of families managing pediatric food allergies, more than a third of parents reported that their child’s allergy had caused them to miss school events, birthday parties, or class activities in the prior year. Not because of a reaction. Because of the fear of one.

The economic cost of pediatric food allergy in the US is estimated at $25 billion annually — roughly $4,200 per child per year. Most of that is not medical treatment. Most of it is dietary substitutions, specialty foods, and lost caregiver productivity.

Anaphylaxis hospitalizations in children increased 150% between 2000 and 2019. About 40% of food-allergic children have had a severe reaction — meaning anaphylaxis — before they receive proper diagnosis and management. The diagnosis often comes after the crisis.

And food allergy is not equally distributed. Black children have substantially higher rates of food allergy-related emergency department visits than white children, even after controlling for income, education, and access to care. Urban children have nearly double the food allergy prevalence of rural children — 9.8% versus 6.2% in US studies. Why? The short answer is we don’t fully know. The longer answer involves the microbiome, farm animal exposure, vitamin D, and something called the hygiene hypothesis — but that’s a separate piece.

One more piece of epidemiology I find remarkable: perceived food allergy prevalence is consistently higher than actual diagnosed prevalence. Studies across Europe show self-reported rates of 10–30% but physician-confirmed rates well under 5%. This matters because children are sometimes placed on elimination diets unnecessarily — with real nutritional consequences — based on family perception rather than confirmed allergy testing.

Where allergies actually start — and it is not where you think

The gut is not the beginning of this story.

For decades, food allergy was framed as a gastrointestinal problem. You eat something, your immune system overreacts in the gut, symptoms follow. It made a certain intuitive sense. But the evidence has been building since the mid-2000s, and by now it’s fairly settled: for many children, the journey to a food allergy begins not in the digestive tract, but on the skin.

This is the dual allergen exposure hypothesis, and it has significant evidence behind it. The basic concept is this: when a child is exposed to a food allergen through an intact gut — during normal feeding — the immune system usually builds tolerance. But when that same allergen enters through a damaged or compromised skin barrier, the immune system does the opposite. It treats the protein as a pathogen. It builds IgE antibodies. It primes mast cells. It learns to react.

The ALSPAC birth cohort study in the UK tracked thousands of children and found that peanut allergy in preschoolers was independently associated with topical exposure to peanut allergen — specifically through application of creams containing peanut oil on inflamed skin during the first six months of life. A separate study found elevated risk of IgE-mediated wheat allergy linked to skin and hair products containing hydrolyzed wheat protein. The peanut never needed to be eaten to sensitize the child. Contact with the skin was enough.

The gene at the center of this is filaggrin (FLG). Filaggrin is a protein that holds the outer skin barrier together. Loss-of-function mutations in FLG — carried by roughly 10% of people of European descent — dramatically increase the risk of eczema, and downstream, food allergy. When the skin barrier leaks, airborne food particles and proteins in skincare products get in. The immune cells waiting just beneath the epidermis — Langerhans cells, mast cells, dendritic cells — see those proteins. And in the context of skin damage and inflammatory signals called alarmins (TSLP, IL-33, IL-25), they learn to regard them as threats.

About 30% of children with moderate-to-severe eczema also have coexisting food allergies. That figure is not a coincidence. Eczema is often the first stop on what immunologists call the Atopic March.

The Atopic March: a map of what happens to these children over time

The Atopic March refers to the typical progression of allergic disease from infancy through childhood and beyond. It generally moves like this: eczema first, often in infancy. Then food allergy, usually by age two or three. Then asthma. Then allergic rhinitis. One condition doesn’t necessarily cause the next — the relationship is partly causal, partly due to shared genetics, partly due to shared immune dysregulation. But they travel together with striking regularity.

A quarter of children with eczema transition to at least one other allergic phenotype. One in five develop multimorbidity — all three conditions together.

What’s interesting — and somewhat counterintuitive — is that the march doesn’t always end in childhood. A longitudinal birth cohort from the Isle of Wight followed participants for 18 years. They found that food allergies resolved during early childhood for many children (about two-thirds of peanut, egg, and sesame allergies resolved between ages 1 and 4 in one cohort). But then there was an uptick in new food allergy sensitization in the teenage years, resulting in higher prevalence at age 18 than in mid-childhood. This pattern is not well understood. Adolescent-onset food allergy is underrecognized, and it may explain why some teenagers who had apparently outgrown allergies report new reactions.

What the immune system actually does when a food allergen is ingested

Here is the molecular sequence, as concisely as I can put it.

Sensitization has already happened — at the skin, or possibly at an early mucosal exposure. IgE antibodies against the allergen are now circulating. They have bound to high-affinity receptors (FcεRI) on mast cells throughout the gut wall. The gut is primed.

When the allergen arrives — in a meal, in trace contamination, in a food that shares proteins with the sensitizing food — it crosses the gut epithelium. It finds those IgE-coated mast cells. It crosslinks the IgE receptors. Within seconds, the mast cells degranulate.

Here is where a 2025 study from Yale, published in Science, overturned a fundamental assumption about what happens next.

The classic model said: mast cells release histamine, histamine causes symptoms, therefore antihistamines should help. But that study found that intestinal mast cells are a distinct subtype from connective tissue mast cells elsewhere in the body. They take their cues from neighboring epithelial cells. And those cues shift their behavior dramatically: intestinal mast cells make relatively little histamine. They ramp up production of cysteinyl leukotrienes instead.

Scientists found that when an allergen is ingested, gut mast cells respond differently from mast cells elsewhere in the body — producing cysteinyl leukotrienes rather than histamine, a finding that helps explain a long-standing puzzle: why IgE antibody levels do not reliably predict food allergy risk, and why food-specific antibodies in the blood are a poor guide to severity.

This is why antihistamines — loratadine, cetirizine, diphenhydramine — don’t stop food-induced anaphylaxis. They block histamine receptors. But the gut is running on leukotrienes.

Mice genetically deficient in cysteinyl leukotriene synthesis were protected from oral antigen-induced anaphylaxis, while those treated with zileuton, a drug already approved for asthma, showed similar protection. This has immediate clinical implications that are now being studied.

Astonishing finding: food aversion is the immune system working

Let me tell you about a 2023 paper in Nature that I think is one of the most underappreciated findings in allergy research in years.

The question the researchers asked was this: if food allergies are so dangerous, does the body develop any behavioral defense against eating the offending food? The answer, it turns out, is yes. A precise, molecular, neurologically-mediated one.

Using mouse models of food allergy, researchers showed that allergic sensitization drives antigen-specific avoidance behavior. Allergen ingestion activates brain areas involved in the response to aversive stimuli — including the nucleus of the tractus solitarius, the parabrachial nucleus, and the central amygdala. Allergen avoidance required IgE antibodies and mast cells, but — crucially — it preceded the development of gut allergic inflammation.

Read that last clause again. Food aversion develops before visible gut inflammation. The brain gets the signal first. And the signal comes not from histamine — blocking histamine receptors had no effect on aversion — but from cysteinyl leukotrienes and a molecule called GDF15 (growth and differentiation factor 15), which is known from other contexts as a signal of cellular stress and tissue damage.

The working hypothesis the researchers proposed is this: allergen is sensed in the gut mucosa through allergen-specific IgE on tissue-resident mast cells. Those mast cells release cysteinyl leukotrienes, which mediate GDF15 secretion, which signals the brain through pathways we don’t yet fully understand — but that activate the same neural circuits involved in disgust, nausea, and fear learning.

The child who refuses to eat eggs after one bad reaction is not being dramatic. Their immune system has updated the brain’s threat model. The brain now treats that food as a poison.

This may also help explain something I see in clinic that has never had a satisfying explanation: children with food allergies sometimes develop aversion to safe foods — foods they have never reacted to, foods that don’t share proteins with their allergens. The theory is that repeated experience of nausea and distress during meals, driven by sub-clinical immune activation, generalizes. The whole act of eating becomes threatening. Food becomes suspect.

Food aversion, ARFID, and the disorder hiding in plain sight

Which brings me to ARFID.

Avoidant/Restrictive Food Intake Disorder is a feeding disorder characterized by extreme selectivity — not driven by body image concerns, not by fear of weight gain, but by fear of adverse food reactions, sensory aversion, or near-complete disinterest in eating. It was added to the DSM-5 in 2013, replacing the older, narrower category of “feeding disorder of infancy and early childhood.”

A study involving 54 children with food allergies who were patients at a food allergy clinic found that more than half met the criteria for probable ARFID. More than half. In a population that, by definition, already has a medically justified reason to avoid certain foods.

This matters because there’s a diagnostic trap here. When a child with, say, a peanut and tree nut allergy also refuses milk, eggs, berries, chicken, and everything except white rice and plain pasta — clinicians may attribute all of it to the known allergy. The genuine ARFID component is missed. Nutritional deficiencies follow. Growth is affected.

Children on allergen elimination diets showed more picky eating and feeding problems overall, with picky eating linked to lower weight-for-age z-scores, food refusal, constipation, and anticipatory gagging.

And the relationship runs in both directions. ARFID can predate a food allergy diagnosis — and having ARFID-like behaviors may actually complicate food challenge testing, because a child who is already highly aversive is harder to evaluate.

Children with food allergies often show heightened anxiety about eating and a tendency to avoid new or potentially allergenic foods — patterns that mirror the restrictive eating seen in ARFID. The constant vigilance required to avoid allergens can lead to heightened anxiety and fear around food, increasing the risk of developing ARFID.

What I wish more families knew: this is treatable. ARFID in the context of food allergy is not a character flaw or a parenting failure. It has a neurobiological basis that we now understand much better than we did five years ago. Cognitive behavioral therapy adapted for food allergy ARFID (CBT-AR) has shown that after 12 weeks, 85% of children achieve meaningful improvement in food variety and anxiety reduction. Specialized feeding clinics that start with children eating an average of three foods regularly get them to 19 foods after intensive therapy. These are real, achievable changes.

Facts about food allergy that most families — and some clinicians — don’t know

Let me take a brief detour from mechanism to give you the kind of trivia that genuinely matters.

1. Peanuts are not tree nuts. Botanically, peanuts are legumes — in the same family as lentils, peas, and soybeans. A child allergic to peanuts has about a 25–40% chance of also being allergic to tree nuts, but the allergy is to a different protein family. Managing a peanut allergy does not automatically mean a tree nut allergy, and vice versa.

2. The top nine allergens now include sesame — and the addition changed menus overnight. In 2023, sesame became the 9th major allergen in the US under the FASTER Act. This created an unexpected problem: manufacturers who had been using sesame as a “hidden” ingredient were now required to declare it. Some reformulated to add sesame intentionally so they could label it overtly — which suddenly exposed allergic consumers who had previously been able to eat those products safely. This is still an ongoing controversy.

3. Milk allergy and lactose intolerance are completely different conditions. Lactose intolerance is a digestive issue — absence of the enzyme lactase. No immune system involvement, no IgE, no anaphylaxis risk. Milk allergy is an immune response to milk proteins (casein, whey). A child with true milk allergy can have anaphylaxis from a trace of dairy. A child with lactose intolerance just has gastrointestinal discomfort. Treating them the same way is a medical error.

4. About 20% of peanut allergies resolve naturally by early adulthood. Roughly 80% of egg allergies do the same. Milk allergy also resolves in most children who develop it in infancy, usually by age 5. Shellfish and tree nut allergies, on the other hand, rarely resolve. Persistence rates for those are over 90%. The natural history varies enormously by allergen and by the severity of the initial sensitization.

5. IgE level does not predict reaction severity. This surprises patients every time I explain it. A child with a sky-high peanut-specific IgE may have only mild symptoms on challenge. A child with a low IgE may have anaphylaxis. The relationship is statistical, not deterministic. Skin prick test wheal size and IgE titer help guide clinical decision-making but they are not oracles.

6. The threshold dose for reaction varies by 1,000-fold between individuals. Some children react to a fraction of a milligram of peanut protein. Others can tolerate hundreds of milligrams before they react. This is why blanket “may contain” warnings are so hard for families to navigate — and why some families make reasonable risk-adjusted decisions to eat products with precautionary labeling while others cannot.

7. Urban children have nearly double the food allergy rate of rural children. Urban US children: 9.8% food allergy prevalence. Rural US children: 6.2%. The “farm effect” — regular exposure to barn animals, unpasteurized milk, diverse microbial environments — appears genuinely protective. This fits with the hygiene hypothesis and the biodiversity hypothesis of allergy, which suggests that reduced microbial diversity in the modern gut microbiome impairs immune regulation.

8. Food allergy prevalence differs by geography in ways that map to diet, not just genetics. In North America and Northern Europe, peanut and egg allergies predominate. In Asia, shellfish and fish allergies are more common. This is not purely genetic — it reflects which foods are introduced early, in what form, and in what cultural context. The LEAP trial (Learning Early About Peanut Allergy) found that introducing peanut early — in the first year of life, before age 11 months — reduced peanut allergy by 81% in high-risk infants compared to avoidance. We spent decades telling parents to avoid peanuts in infancy. We were wrong.

The treatment landscape, honestly

There are currently two FDA-approved treatments for food allergy.

Palforzia (2020): a characterized peanut protein powder used for oral immunotherapy (OIT) in children aged 4–17 with peanut allergy. The goal is desensitization — not a cure, but an increase in the threshold dose required to trigger a reaction. This gives families a meaningful safety buffer. The catch: OIT requires daily dosing, strict adherence, and can itself cause reactions. About 10–15% of patients discontinue due to adverse effects. Sustained unresponsiveness — the ability to tolerate peanut even after stopping regular exposure — occurs in a minority.

Omalizumab (Xolair) (2024 new indication): originally approved for allergic asthma and chronic urticaria, omalizumab was approved in 2024 for IgE-mediated food allergy in patients 1 year and older. It works by binding free IgE in the blood before it can attach to mast cells. In the OUtMATCH trial, 67% of omalizumab-treated patients were able to tolerate at least 600 mg of peanut protein without a dose-limiting reaction, compared to 7% in the placebo group. Similar results held for milk, egg, and cashew. Omalizumab does not cure the allergy. It raises the threshold and buys time for OIT or reduces risk of accidental exposure reactions. But for a child with multiple food allergies who cannot complete OIT — it is a real, meaningful option.

What’s coming: targeting the cytokine pathways upstream. Dupilumab (anti-IL-4Rα), already approved for atopic dermatitis and asthma, is in trials for food allergy and for preventing the Atopic March in infancy. The idea is to interrupt sensitization before it solidifies. Blocking IL-9, which drives mast cell expansion in the gut, is an active research target. And — given the 2025 Science data — drugs that block leukotriene production or receptor binding are now being seriously evaluated for food allergy, rather than just asthma.

The gut microbiome is also a therapeutic target. Fecal microbiota transplantation (FMT) combined with peanut OIT is in clinical trials. The microbiome connection is strong enough epidemiologically — formula-fed infants, C-section births, early antibiotic courses all increase allergy risk — that manipulating it therapeutically is a reasonable hypothesis. We don’t have outcomes data yet. But the mechanistic case is there.

And then there is skin barrier intervention. Several trials are now examining whether aggressive moisturization in the first weeks of life — before the skin barrier has a chance to be disrupted — can reduce the rate of sensitization through the skin. The PEBBLES pilot study found trends toward reduced food sensitization at 12 months in infants treated with emollients five or more days per week. Larger trials are ongoing. The concept is elegant: fix the door before the trespasser gets in.

What this means at the dinner table

I am aware that everything I’ve described above — the leukotrienes, the ALOX5 pathway, the cysteinyl mediators — is a long way from Wednesday night dinner with a child who won’t eat.

So let me translate it.

If your child has food allergy and also has food aversion that seems disproportionate — refusing safe foods, gagging at smells, meals that are battles — please take it seriously as a distinct clinical problem. It is not manipulation. It is not anxiety for no reason. There is a molecular basis for that child’s relationship with food, and it can be addressed.

If your child is on an allergen elimination diet and their weight gain has slowed, or they’ve started refusing foods they used to eat, or mealtimes are consistently distressing — these are signs to escalate, not wait out.

If you’re a parent modeling anxiety at mealtimes — constantly checking labels with visible stress, tasting everything before your child, rehearsing emergency protocols in front of them — that anxiety communicates. The data on parent behavior and ARFID risk is consistent: children take cues. Calm, matter-of-fact allergen management paired with a rich relationship with safe foods is the target.

And if you have been told your child just needs to “try harder” or “stop being dramatic” about food — I want you to know that’s not what the science says. The science says that an allergic child’s brain has been trained, by their own immune system, to treat certain foods as existential threats. That is a medical condition. It deserves medical attention.

Where I think this goes

The next decade in food allergy is going to be about prevention more than treatment. The signals are there.

We know sensitization starts at the skin. We know the window for primary prevention may be the first weeks and months of life — before the immune system has locked in its responses. We know that early dietary introduction of common allergens reduces allergy risk substantially. We know that maintaining gut microbial diversity appears protective. We know that skin barrier repair may interrupt the Atopic March before it starts.

None of this means we’ll eliminate food allergy. But moving even part of the burden from management to prevention would change the lives of millions of families who currently spend their days reading ingredient labels, carrying epinephrine, and fielding calls from school nurses.

I think about the families I see in clinic. I think about the child who ate at the lunch table alone because the cafeteria was too risky. The teenager who stopped going to birthday parties. The parent who hasn’t taken a vacation in four years because foreign kitchens are too unpredictable. These are not small inconveniences. They are the texture of a life shaped around an immune error.

The biology behind that error is now more understood than at any point in history. The treatments are improving. The prevention framework is being built.

That doesn’t fix this week’s dinner. But it means the trajectory is going somewhere better.

If you found this useful, share it with a family managing food allergy. The most dangerous myth in this space is that nothing can be done.

Sources: Nature (2023), Science (2025), Frontiers in Immunology (2025), NCBI StatPearls (2025), Journal of Allergy and Clinical Immunology, CDC NCHS Data Brief, World Allergy Organization Journal, ScienceDaily, Begin Health/ERC clinical reviews.

There’s a plant growing in English hedgerows and cottage gardens right now that contains one of the most medically useful — and most dangerous — chemicals in the history of pharmacy. Gardeners grow it for its tall spires of purple bells. Bees love it. Children’s books feature it. And for about 240 years, doctors have been carefully, nervously, extracting its chemistry to keep failing hearts alive.

The foxglove. Digitalis purpurea. Unremarkable to look at. Extraordinary to understand.

What follows isn’t a wellness post. It’s a story about a plant that sits at an almost uncomfortably thin line between medicine and poison — and how researchers in 2025 and 2026 are discovering it might have a completely different career ahead of it, one involving your immune system and some of the hardest-to-treat cancers we know.

How a Birmingham Doctor Changed Everything

The year is 1775. A physician named William Withering is working in Birmingham, England, and one of his patients — a woman with severe edema, the kind where fluid fills the body cavities and the legs swell grotesquely — has run out of options. The standard treatments aren’t working. Withering expects her to die.

Then he discovers she’s recovered. Not through his ministrations. She’d been quietly taking a herbal concoction from a local woman in Shropshire. Withering, who happened to be a gifted botanist as well as a physician, looked at the mixture of twenty-odd herbs and immediately recognized the likely active ingredient.

Foxglove.

He spent the next ten years methodically documenting every case he treated with it. Not cherry-picking the successes — a level of scientific honesty remarkable for his era. He included failures, toxicities, and patients who died. In 1785, he published An Account of the Foxglove and Some of Its Medical Uses, describing 158 patients. Of those, 101 with congestive heart failure got better. His dosing calculations were so precise that modern analysis puts them only slightly below what we use today.

“Truth and Science would condemn the procedure. I have therefore mentioned every case... proper or improper, successful or otherwise.”
— William Withering, 1785

That book is one of the most important documents in pharmacological history. Withering knew it. His portrait — the only one from life — shows him holding a foxglove sprig. His epitaph at Edgbaston Old Church is carved with the plant. The man and the flower became inseparable.

What he didn’t know, and what took another century to understand, was whyit worked.

The Chemistry of the Foxglove

The foxglove produces a class of chemicals called cardiac glycosides — the name a clue to their structure: a sugar molecule attached to a steroid-like core. The plant makes them presumably as a defense against insects. For mammals with hearts, these compounds do something very specific and very powerful.

They block a molecular pump called Na⁺/K⁺-ATPase — an enzyme embedded in every heart muscle cell that normally shuffles sodium out and potassium in. When you block this pump, sodium accumulates inside the cell, causing calcium to flood in. More calcium means stronger, more forceful contractions.

In a weakening heart, that’s the difference between barely pumping and actually pumping.

The main pharmaceutical compounds extracted from foxglove are three siblings with distinct personalities:

Digoxin (from Digitalis lanata, the woolly foxglove): The one most doctors and patients have heard of. A “positive inotrope” — it makes the heart beat harder. It also slows the heart rate by affecting the electrical conduction system, which makes it useful for atrial fibrillation: the fast, chaotic rhythm that affects millions of people.

Digitoxin (from Digitalis purpurea, the common purple foxglove): The older sibling. Similar mechanism, longer-acting, and critically — cleared by the liver rather than the kidneys. This matters more than it sounds, as we’ll get to.

Lanatoside C: A faster-acting glycoside used in acute situations where you need to stabilize a rhythm quickly and can’t wait for slower-clearing agents to take effect.

FIGURE 1 — PLACEHOLDER

Purple foxglove (D. purpurea) vs. Woolly foxglove (D. lanata): leaf morphology comparison, distribution of active glycoside content by plant part, and primary commercial growing regions for pharmaceutical extraction

The Narrow Window

Here’s what makes foxglove so peculiar as a medicine. Its therapeutic window — the gap between “helpful dose” and “harmful dose” — is one of the narrowest in all of pharmacology. The dose that strengthens a failing heart sits uncomfortably close to the dose that causes fatal arrhythmias.

THE NUMBERS

The blood level of digoxin that helps a heart failure patient sits around 0.5–0.9 nanograms per milliliter. Toxicity begins at roughly 2 nanograms per milliliter. For context: a human hair is about 70,000 nanograms. We’re managing people on differences that are invisible to the naked eye.

Withering noticed this in 1785. He described toxicity symptoms with clinical clarity that would be recognized by any emergency physician today: irregular pulse, visual disturbances including a famous yellow-tint to vision, nausea, and ultimately fatal rhythm disturbances. The Victorians called it “foxglove sickness.” Modern medicine calls it digitalis toxicity, and it still kills people who are overdosed or whose kidney function changes unexpectedly.

This toxicity is why, over the last few decades, digoxin prescriptions declined sharply. Newer drugs — beta-blockers, ACE inhibitors, SGLT2 inhibitors — arrived with better safety profiles and more predictable behavior. Digoxin was increasingly treated as a relic of an earlier era.

Then, in August 2025, a clinical trial made a lot of cardiologists look up from what they were doing.

The DIGIT-HF Trial: Digitoxin’s Comeback

The DIGIT-HF trial — a double-blind, placebo-controlled study from 55 sites across Germany, Austria, and Serbia — enrolled 1,240 patients with advanced heart failure and reduced ejection fraction. These were sick patients: most were in NYHA class III (symptomatic at minimal exertion), and all were already on contemporary guideline-directed therapies including the newer drugs that have transformed heart failure treatment.

The question was whether adding digitoxin — not digoxin, but its liver-cleared cousin — would make any additional difference.

Published in the New England Journal of Medicine in August 2025, the answer was yes. Digitoxin reduced the combined risk of death from any cause or hospitalization for worsening heart failure by an absolute 4.6 percentage points over a median follow-up of three years.

The effect size is modest. But what makes it interesting is the population and the mechanism. The benefit held across patients taking modern quadruple therapy — the most aggressive current treatment protocol.

And the lead investigator specifically called out that digitoxin may be particularly useful for patients with impaired kidney function: precisely the population that struggles most with digoxin’s renal clearance requirements.

Because digitoxin is cleared by the liver, its blood concentrations remain stable even as kidney function deteriorates. No complex dose adjustments every time creatinine creeps up. No panic when a heart failure patient’s kidneys — which often go hand-in-hand with the failing heart — start to worsen. For clinicians managing this very common and very difficult combination, that’s a practically meaningful difference.

The Part Nobody Expected: Cancer

Here is where the foxglove’s story takes a turn that would have genuinely astonished William Withering.

The same Na⁺/K⁺-ATPase pump that foxglove glycosides inhibit in heart muscle cells is overexpressed in multiple cancer cell types. When you block it in a cancer cell, the consequences are considerably more lethal than in a normal cell. Cancer cells, with their high metabolic demands and already-stressed physiology, are more vulnerable to the disruption of ionic balance.

Laboratory studies have shown that digitalis-derived compounds are highly cytotoxic — cell-killing — against a range of human cancer cell lines. The mechanism involves triggering apoptosis: the cell’s own programmed self-destruction pathway, which cancer cells have typically evolved to evade. Forcing that pathway back on is something oncologists have been trying to do with many different compounds.

More intriguing is research targeting cancer stem cells — the small subpopulation of cells within a tumor that are most resistant to conventional chemotherapy, and that are thought responsible for relapse and metastasis after treatment appears successful. Early research suggests that cardiac glycosides may have activity against this population that standard chemotherapy misses entirely. The mechanism isn’t fully established, but it involves the same pump inhibition affecting stem cell signaling pathways.

This is preclinical data. It would be dishonest to call it a cancer treatment. But it’s enough that multiple research groups are pursuing it — and it intersects with a much larger and stranger story about the immune system.

RORγt: The Molecular Switch Nobody Knew Was There

In 2006, immunologists identified a transcription factor — a molecular switch that controls gene expression — called RORγt (pronounced “ROR-gamma-t”). It turned out to be the master regulator of a class of immune cells called Th17 cells.

Th17 cells produce a signaling molecule called IL-17. When these cells are overactive, they drive inflammatory and autoimmune conditions: rheumatoid arthritis, psoriasis, inflammatory bowel disease. Block RORγt, the logic went, and you suppress Th17-driven inflammation. Pharmaceutical companies began racing to find oral drugs that could achieve what expensive injectable biologics were already doing.

2006

RORγt identified as the master regulator of Th17 cell differentiation — immediately flagged as a high-value drug target for autoimmune disease

2011

A Nature paper reports that digoxin — the foxglove drug — binds to the RORγt ligand-binding domain and blocks Th17 differentiation. A completely separate mechanism from anything happening in the heart

2012–2017

Major pharmaceutical investment in RORγt inhibitors. Clinical trials run against autoimmune indications. Results are underwhelming versus biologics; safety concerns emerge around thymic T-cell effects

2018–2023

The inhibitor program cools off. But separately, researchers begin looking at what happens when you go the other direction — activating RORγt rather than suppressing it

2024–2026

The oncology pivot: RORγt agonists enter early clinical trials to “heat up” cold tumors and make them visible to checkpoint immunotherapy. Digoxin’s role as the molecule that first mapped this receptor comes back into focus

The Flip: From Suppressor to Activator

Researchers had been thinking about RORγt as something to switch off — to dampen overactive inflammation. The oncology pivot asked a different question: what if you switched it on?

In cancer, a well-documented problem is the cold tumor: a tumor that has managed to exclude immune cells from its microenvironment, making itself essentially invisible to the body’s defenses. Checkpoint inhibitors — the cancer drugs that have transformed oncology over the last decade — work best in tumors already infiltrated by immune cells. Cold tumors don’t respond nearly as well. And many common cancers run cold.

RORγt agonists — molecules that activate rather than block the receptor — appear capable of recruiting immune effector cells into cold tumor environments. The Th17 pathway, when activated appropriately in a tumor context, can drive an immune infiltration that checkpoint inhibitors then amplify. You warm the tumor up first, then send in the blockers.

This is not science fiction. A first-in-class synthetic RORγt agonist — cintirorgon (LYC-55716) — completed a Phase 1 trial in patients with relapsed or refractory metastatic cancers. No dose-limiting toxicities occurred among the 32 enrolled patients across a range of doses, and early antitumor signals were observed.

The foxglove connection here is structural and mechanistic rather than direct. Digoxin and its derivatives were first used to map the RORγt binding site and to demonstrate its functional importance. The synthetic agonist programs that followed built on that knowledge. Whether digitalis-derived molecules themselves will be developed as RORγt agonists remains an open question — the margin between their cardiac effects and their immunological effects requires careful pharmacological navigation — but the research is active.

The Dose Makes the Poison — and the Medicine

What connects all of these threads is a concept that goes back to the 16th-century physician Paracelsus: sola dosis facit venenum. The dose alone makes the poison.

Foxglove at high concentrations: cardiac toxicity, fatal arrhythmias, death.

At therapeutic concentrations in a failing heart: life-saving inotropy and rate control.

At lower concentrations affecting RORγt: immune modulation with potential autoimmune and oncologic applications.

At concentrations affecting cancer cell pumps: potential cytotoxicity against tumor cells that overexpress the target.

The same molecule. Different doses. Wildly different biological conversations.

This is a recurring pattern in pharmacology, but foxglove makes it almost embarrassingly legible. It’s a chemical with so many conversations going on with the human body that we are still — 240 years after Withering’s book — finding new ones.

The Flavonoids — The Part Nobody Talks About

The cardiac glycosides get all the attention, but foxglove leaves contain other compounds that researchers are only now beginning to characterize seriously.

One is scutellarein, a flavonoid with antioxidant properties entirely separate from any cardiac effect. Early research suggests anti-inflammatory activity through mechanisms distinct from the glycoside pathway. It’s far too early to say where this leads, but it illustrates a broader point: plants are not single-compound factories. The foxglove leaf is a complex biochemistry experiment, and we’ve mostly been studying one product line.

Traditional medicine systems — particularly in parts of India — have used topical preparations of digitalis glycosides in ointments for severe burns, where the compounds are thought to stimulate local circulation and aid tissue healing. This sits outside mainstream Western pharmacology and hasn’t been rigorously studied in clinical trials. But it’s not implausible given what we understand about vascular effects. It’s a loose thread, and loose threads sometimes lead somewhere.

What We Know, What We Don’t

The honest position on foxglove in 2026:

Well-established: Digoxin and digitoxin are real medicines with real cardiovascular applications. The DIGIT-HF trial provides solid evidence that digitoxin reduces hospitalization and death in certain heart failure patients, particularly those with renal impairment. Both carry a genuinely narrow therapeutic window requiring careful clinical management.

Promising but not proven: Anticancer applications of cardiac glycosides are an active and intriguing area of lab research. The findings are consistent across multiple cell line studies. Clinical validation in humans is limited.

Scientifically coherent but speculative: The path from “digoxin binds RORγt” to “foxglove-derived molecules treat cold tumors” runs through a lot of unsolved pharmacological and safety problems. The synthetic agonist programs inspired by this discovery are further along than the digitalis-derived work itself.

Withering’s own instinct, looking at his 1785 data, seems right for 2026 as well: document everything, claim only what the evidence supports, and leave room for what comes next.

The foxglove has been growing in the hedgerows for millions of years. Its chemistry has been tested in folk medicine for centuries, in systematic clinical trials for 240 years, and in molecular biology laboratories for the last few decades. Every time we think we understand what it does, it shows us another room.x

That’s either a sign of a very strange plant, or a sign of how much we still have to learn about the cells we’re made of.

SOURCES & FURTHER READING

• Bavendiek U et al. “Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction.” N Engl J Med2025;393(12):1155–1165.

• Karaś K et al. “Digoxin, an Overlooked Agonist of RORγ/RORγT.” Frontiers in Pharmacology 2018;9:1460.

• Withering W. An Account of the Foxglove and Some of Its Medical Uses. Birmingham: M. Swinney, 1785.

• Mahalingam D et al. “Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon).” Clin Cancer Res 2019;25(12):3508–3516.

• “Digitalis – from Withering to the 21st century.” British Journal of Cardiology, August 2024.

• Nature Reviews Cardiology. “Benefit of digitoxin therapy for HFrEF.” Vol. 22, p. 842, September 2025.

Here’s why sleep loss deserves the same attention as diabetes—and what it means for drug development.

The Metabolic Chaos of Sleep Loss

Like diabetes, sleep deprivation disrupts how your body handles glucose, ramps up inflammation, and throws your metabolism into disarray. A 2015 Science Signaling review (DOI: 10.1126/sciadv.1504018) shows that just 4–6 hours of sleep deprivation in mice spikes adenosine levels in the hippocampus, impairing glucose uptake and mimicking insulin resistance seen in diabetes. This isn’t just a brain issue—peripheral tissues like adipocytes also show reduced insulin sensitivity, leading to fat accumulation and oxidative stress. For drug developers, this points to a clear target: metabolic pathways disrupted by sleep loss.

Inflammation and Oxidative Stress: A Shared Culprit

Sleep loss doesn’t just tire you out; it ignites a firestorm of inflammation. The Science Signaling study found that sleep deprivation boosts oxidative stress proteins and lipid droplet accumulation in glial cells, which then rely on β-oxidation to cope. This mirrors the chronic inflammation in diabetes, where oxidative stress damages tissues and drives complications like cardiovascular disease. In the context of hypertrophic cardiomyopathy (HCM), a condition linked to sudden death in young athletes, sleep deprivation could amplify inflammation, worsening cardiac fibrosis. Therapies targeting oxidative stress—like antioxidants or anti-inflammatory biologics—could address both sleep loss and diabetes-related damage.

Synaptic and Systemic Fallout

The brain takes a hit from sleep loss, much like it does in metabolic disorders. The study highlights how sleep deprivation downregulates neural plasticity by increasing adenosine and A1R activity, leading to memory deficits. This is eerily similar to diabetes-induced cognitive decline, where poor glucose metabolism harms neurons. Systemically, sleep loss redirects energy away from non-essential processes, like synapse formation, to cope with metabolic stress—paralleling diabetes’ energy misallocation. Drug developers could explore adenosine receptor antagonists or neuroprotective agents to mitigate these effects, potentially benefiting both conditions.

HCM and Sleep: A Deadly Combo

For those with HCM, sleep deprivation could be a silent killer. The Science Translational Medicine study (DOI: 10.1126/scitranslmed.aad2516) showed that inflammation drives HCM’s progression, with regulatory T cells (Tregs) struggling to control it. Sleep loss exacerbates this by upregulating inflammatory pathways, potentially increasing the risk of sudden cardiac death in young athletes. Imagine a college basketball player, burning the candle at both ends, unaware that their heart is under extra strain. Therapies like IL-2 agonists (e.g., sifalimumab) or PD-1 agonists, which boost Treg function, could tackle inflammation in both HCM and sleep-deprived patients, offering a dual-purpose pipeline.

Drug Development Opportunities

The parallels between sleep loss and diabetes open exciting avenues for drug development:

• Adenosine receptor modulators: Blocking A1R could restore neural plasticity and glucose metabolism, addressing cognitive and metabolic deficits.

• Anti-inflammatory biologics: IL-2 or PD-1 agonists, inspired by HCM research, could reduce systemic inflammation, benefiting both sleep-deprived and diabetic patients.

• Antioxidants: Targeting oxidative stress could protect tissues from the damage caused by sleep loss and diabetes.

• Insulin sensitizers: Drugs like metformin might be repurposed to improve glucose uptake in sleep-deprived individuals.

Clinical trials could focus on biomarkers like adenosine levels, inflammatory cytokines, or LGE-CMR for fibrosis, accelerating the path to market for these therapies.

Why It Matters for You

Sleep loss isn’t just about feeling groggy—it’s a metabolic crisis that could shorten your life, especially if you’re at risk for conditions like HCM. For drug developers, it’s a call to action: prioritize sleep as a therapeutic target with the same urgency as diabetes. The science is clear, and the stakes are high.

Want to stay ahead on groundbreaking therapies? Subscribe to www.drugdevelop.com for the latest in cardioimmunology, metabolic disease, and more. Let’s wake up to the power of sleep—and save lives in the process.

Citations:

1. [Authors]. (2015). Sleep loss is a metabolic disorder. Science Signaling, 8, adp9358. DOI: 10.1126/sciadv.1504018

2. Wang, Y.-J., et al. (2015). Regulatory T cells attenuate chronic inflammation and cardiac fibrosis in hypertrophic cardiomyopathy. Science Translational Medicine, 7, eaad2516. DOI: 10.1126/scitranslmed.aad2516

As multi‑specific antibodies move from concept to clinic, the ecosystem around trial design, PD readouts, and safety surveillance is being rewritten. A useful case study is HXN‑1002, theα4β7 × TL1A bispecific licensed to Sanofi in 2025 for inflammatory bowel disease. It pairs vedolizumab‑like gut trafficking inhibition with TL1A neutralization, aiming for synergy in patients who have cycled through multiple biologics. But its significance lies not only in its targets—it reflects a broader shift in how the field is beginning to view multi‑pathway modulation.

Theoretical advantages

Bispecifics promise to solve a core I&I problem: single‑pathway agents rarely control the full inflammatory network. Insufficient depth of suppression is common, and switching between classes often yields diminishing returns.

In theory, multi‑specifics offer:

• Mechanistic stacking without polypharmacy. The goal is to combine two validated mechanisms in one scaffold, reducing variability in exposure and avoiding drug–drug PK interactions.

• Spatial and temporal coupling of pathway inhibition. In models where TL1A signaling potentiates pathogenic lymphocyte trafficking, a bispecific can theoretically shut the loop more efficiently than two independent mAbs.

• Potentially lower systemic immunosuppression. When one arm is tissue‑selective (e.g., α4β7), it may confine systemic consequences of blocking the second pathway.

But these theoretical advantages come with more realistic constraints.

Realistic disadvantages

1. The biggest limitation is biological: two targets do not always equal synergy. Many bispecific programs in oncology demonstrated clean target engagement but little clinical differentiation because each arm remained only modestly effective alone. In I&I, too, a molecule may achieve “dual engagement” without meaningful biological integration.

2. A common issue from earlier IL‑17 × TNF or IL‑12/23 × IL‑17 explorations was imbalanced receptor occupancy: one arm saturated early while the other lagged, leaving only single‑pathway inhibition at practical doses. HXN‑1002’s designers aim to avoid this by using an antibody architecture with similar affinity ranges and matched pharmacokinetics across arms, but FOIH data will determine whether this theoretical balance translates in vivo.

3. Another constraint is the dose ceiling. When one arm drives toxicity, it caps the achievable exposure of the other. For example, early dual‑cytokine antibodies often hit cytokine‑release ceilings before reaching target saturation for the second pathway. The α4β7/TL1A pair is attractive partly because neither arm has historically caused dose‑limiting systemic toxicity, but that assumption still has to be tested under dual blockade.

How to tell multispecifics may be differentiated from monospecifics?

HXN‑1002 illustrates where multi‑specific trials need more disciplined biomarker integration. Dual‑arm receptor occupancy assays—α4β7 flow cytometry paired with TL1A ligand‑displacement—provide a direct map of whether both mechanisms are actually engaged simultaneously. Programs that neglected such assays (e.g., some first‑generation TNF × IL‑17 constructs) struggled to interpret flat clinical curves because it remained unclear whether the biology or the exposure was the problem.

Similarly, PD markers such as fecal calprotectin, CRP, and Th17‑related cytokines can reveal whether blocking TL1A adds anything beyond gut‑selective trafficking inhibition. In the vedolizumab era, calprotectin often fell more slowly than clinical symptoms; TL1A suppression may accelerate these kinetics, and early PD acceleration could be a key differentiator for bispecific success.

Anecdotally, some IL‑23 × IL‑17 early‑phase programs saw sharp histologic signals before clinical remission—suggesting histology may be one of the earliest windows into bispecific synergy. This makes centralized Geboes/Robarts scoring even more relevant for HXN‑1002.

The Real Safety Questions

Although α4β7 selectivity should reduce systemic immunosuppression, dual inhibition introduces unique risks. One concern is prolonged trafficking blockade in TL1A‑high individuals, potentially extending infection liability. This is analogous to early natalizumab experiences where patients with high α4 integrin expression demonstrated longer receptor‑recovery kinetics than expected.

There is also a theoretical—but important—concern around neurologic risk. Even gut‑selective integrin blockade commands vigilance, because small perturbations in lymphocyte trafficking can lead to rare but serious events, even if risk is materially lower than with α4β1‑active agents. The prudent approach is tight infection surveillance, immunophenotyping, and PK/PD‑guided titration to avoid overshooting on either arm.

Why This Matters for 2026–2028 Pipelines

HXN‑1002 represents a new class of multi‑specifics where the biggest differentiators may not be the targets themselves, but the execution: Did the developers capture dual occupancy? Did biomarkers show synergy? Did safety monitoring account for dual‑pathway dynamics?

Bispecifics promise more than mechanism stacking—they promise precision stacking. But the programs that succeed will be the ones that treat trial design as much a part of the innovation as the antibody itself.

A Poll for the Readers

Which technical challenge worries you most in multi‑specific antibody development?

A) Achieving balanced receptor occupancy

B) Managing dual‑pathway safety interactions

C) Biomarker complexity

D) Dose ceiling imposed by one arm

Drop your vote—and share your bispecific lessons learned. I respond to every comment.

The pharmaceutical industry runs on a crushing paradox. We possess petabytes of biological data—genomic sequences, real world evidence, clinical telemetry—yet we starve for actionable insight. For the Chief Medical Officer or Chief Scientific Officer, the bottleneck is no longer the generation of data. It is the latency of decision.

We operate in an era of manual curation and static spreadsheets. We wait weeks for analysts to translate scientific queries into business intelligence. This “reporting lag” is a strategic liability. The remedy is not more analysts. It is the direct application of Python programming by senior leadership.

This is not a suggestion that executives become software engineers. It is a mandate to become “Citizen Data Scientists.” By acquiring functional literacy in code, leaders can bypass the translation layer and interrogate the universe of data directly. The payoff is Decision Velocity: compressing a five day analysis cycle into a four hour loop.

The Cost of Analogue Inertia

Current business development workflows are plagued by friction. Highly paid experts spend up to 80% of their time finding and cleaning data, leaving a fraction for actual analysis. In licensing and due diligence, this inefficiency manifests as missed opportunities.

Information sits in silos. Biological truth lives in Open Targets. Clinical truth resides in ClinicalTrials.gov. Academic truth is buried in PubMed. Integrating these sources manually is slow and prone to error. A typo in a spreadsheet or a missed trial update can compromise a deal.

Python acts as the connective tissue. It allows for the automated, reproducible amalgamation of these disparate sources. It transforms the browser—a tool for reading single pages—into a script that reads entire libraries.

The Search and Evaluation Loop

Consider the three pillars of the modern data ecosystem: The Target, The Trial, and The Literature. Each offers an Application Programming Interface (API) that allows for direct access.

• The Target: The Open Targets platform aggregates genetics, somatic mutations, and drug data to score target disease associations. Its harmonic sum scoring system filters noise, rewarding strong, repeated evidence while penalizing weak signals. A Python script can query this database in seconds, filtering thousands of targets to find those with high genetic validation but no approved drugs.

• The Trial: The modernized ClinicalTrials.gov API allows executives to map the competitive landscape instantly. A script can calculate recruitment velocity across competitors or visualize “white space” in therapeutic areas where patient needs are high but trial density is low.

• The Literature: PubMed contains the consensus of the scientific community. Python tools like BioPython allow an executive to scan thousands of abstracts for sentiment, measuring the “novelty slope” of a target or flagging safety signals before they appear in a formal report.

Case Study: The JAK Pivot

Consider a Business Development executive evaluating Janus kinase (JAK) inhibitors. These potent immunomodulators are well established in rheumatoid arthritis, but the market is crowded.

Using a manual workflow, identifying a novel niche could take weeks of reading. With Python, the executive queries Open Targets for diseases genetically linked to the JAK pathway. The script filters for dermatological conditions. It identifies Alopecia Areata and Vitiligo as high signal targets.

The script then pivots to ClinicalTrials.gov. It finds the alopecia field is saturated with active trials. However, a query for Granuloma Annulare reveals a different story: strong biological rationale but minimal clinical competition. Finally, a check of PubMed confirms early academic interest with positive case reports.

In minutes, the executive has moved from a broad query to a specific, data backed hypothesis: prioritize Granuloma Annulare. This is the difference between reading the news and making it.

The Cultural Shift

The transition to code is a cultural pivot. When leadership demonstrates data fluency, it signals a shift away from gut feeling toward evidence based strategy. It democratizes data science, bridging the gap between R&D and commercial teams.

The tools are available. The barrier to entry is lower than ever. The senior leader who learns to write the script does not just gain a skill. They gain the autonomy to lead in a complex, high attrition industry where speed is the only currency that matters.

Welcome to the first issue of Biotech Triallist, your go-to source for insights into the high-stakes world of biotech clinical trials.

We’re diving into proof-of-concept (PoC) trials—those make-or-break moments that can launch a therapy to stardom or send it to the morgue.

This issue tackles a critical question: Do you have the right talent and scholarship to make your PoC trial a success?

From the CEO’s vision to the CMO’s expertise and the unsung contributions of nonclinical colleagues, we’ll explore why internal talent is the key to winning in biotech.

Let’s get started!

The CEO: The Strategy Architect 🧭

In a small biotech, everything flows from the business strategy. The CEO is the architect, setting the course for success.

• 📈 Vision setter: The CEO defines the company’s direction, aligning science with market needs.

• 🪨 Stability provider: They must offer resolve to see the strategy through, even when challenges arise.

• 🚫 No vacillation: Wavering on strategy creates chaos, derailing clinical and operational plans.

A CEO’s steady hand is critical in PoC trials. Without a clear company strategy, other efforts—trial design, resource allocation—fall apart.

For example, a biotech company pursuing a novel immunology drug needs a CEO who is committed to a focused indication. Flip-flopping between indications wastes time and money.

A strong CEO ensures the team rows in the same direction. Their resolve empowers the CMO and team to execute with confidence.

The CMO: Your Biotech’s Yoda 🧬

The Chief Medical Officer (CMO) translates the CEO’s vision into clinical reality. They’re the Yoda guiding drug development.

• 🧠 Scientific mastery: A CMO must grasp the drug’s mechanisms and therapeutic area deeply.

• 🩺 Clinical expertise: They understand disease progression and patient needs.

• 🚀 Strategic alignment: They align trials with regulatory and investor goals.

Their expertise is make-or-break.

A weak CMO risks flawed endpoints or missed signals. They must be a therapeutic area expert to steer the trial right. Typically, such therapeutic area experts are board-certified physicians. However, Board certification is necessary but not sufficient.

The Risk of a Mismatched CMO 🔍

You may have seen situations where the CMO is a specialist in A, the SVP in B, the VP in C, and then they try to hire a physician of the right specialty, D, as a medical monitor/ medical director. The problem: The physician in the medical monitor role can assist with some clinical details of day-to-day operations, but is not necessarily qualified or scholarly to guide the clinical program.As a result, the whole clinical trial program is free from people who are appropriately qualified to have a vision and execute it accordingly.

Not good.

A CMO from the wrong specialty—like an oncology CMO in an immunology company or a surgeon CMO in diabetes—risks derailing your trial. Their lack of field knowledge creates gaps.

• 🎯 Therapeutic misalignment: An oncology CMO may miss immune disease nuances.

• 🩺 Clinical blind spots: A surgeon CMO might overlook diabetes endpoints, such as A1C.

• 📜 No historical context: They don’t know past failures or precedents, risking errors.

A mismatched CMO also struggles with the field’s ecosystem, limiting their impact.

• 🌟 Wrong KOLs: They contact irrelevant experts, missing key insights.

• 🤖 Blindly parrots KOL views: They don’t have the domain expertise to assess advice critically.

• 📊 Unreliable data: They may trust flawed primary sources, skewing the strategy.

• 📍 Poor site selection: They don’t know which clinical sites perform or which to avoid.

The Value of Nonclinical Colleagues 🌱

Nonclinical colleagues are unsung heroes in PoC trials. Their expertise shapes smarter decisions.

• 🧩 Prior experience: They bring lessons from past projects, dodging old pitfalls.

• 📚 Deep knowledge: Their scientific or operational insights inform strategy.

• 💡 Critical thinking: They challenge assumptions, refining approaches.

Their historical knowledge and anecdotes are gold. These insights guide trial success.

• 📜 Precedents: They know what’s failed before, saving resources.

• 🗣️ Anecdotes: Their stories reveal practical challenges, like site quirks.

A nonclinical scientist might recall a failed trial due to a poor biomarker. This could steer your PoC trial to victory.

The Pitfalls of Consultants 📉

Consultants seem budget-friendly, but they fall short in PoC trials.

• 🔄 No skin in the game: They advise and leave, lacking commitment.

• 📚 Limited context: They’re rarely privy to proprietary data.

• ⏰ Short-term focus: They can’t tackle iterative challenges.

External advisors risk fragmented strategies. You need leaders who live your mission.

You cannot outsource strategy or tactics (to KOLS, CROs, and such). The company owns it. If the company cannot do it, maybe it is not in the right business.

Why KOLs Aren’t Enough 🌟

KOLs bring prestige, but they can’t lead PoC trials.

• 🩺 Narrow focus: They excel in their niche but lack development expertise.

• 🧑🏼‍🎓 No Industry experience: Professors live in a different milieu and often have no clue how drug development works

• 🔒 Limited data access: They’re not privy to confidential results.

• 📊 Strategic disconnect: They might prioritize publications over regulatory needs.

A KOL might push for a splashy data release. A competent CMO knows its implications.

KOLs validate, but they don’t replace internal leadership.

The Power of Full-Time Talent 💼

Small biotechs run lean, but skimping on talent is a mistake. Full-time experts deliver.

• 🤝 Continuity: A CMO builds trust with investors and regulators.

• 🔥 Commitment: They’re invested in long-term success.

• 🧩 Holistic insight: They see the full picture, from lab to trial.

Studies like Noticewala et al. (JNCI, 2025) show industry trials succeed due to focus. Internal teams drive that.

Full-time talent isn’t just roles. It’s a team that’s all in.

How to Build the Right Team 🛠️

Assembling a PoC dream team takes deliberate choices. Here’s how.

• 🔍 Hire domain experts: Your CEO, CMO, and team need therapeutic expertise.

• 🌱 Foster scholarship: Encourage journal clubs or such for innovation.

• 🤝 Align incentives: Offer equity and mission-driven goals.

A CMO who asks, “Does this endpoint reflect our drug’s mechanism?” elevates trials. Curiosity fuels breakthroughs.

Don’t settle for mismatched talent. Seek thinkers who thrive in chaos.

Looking Ahead: The Stakes Are High 🚀

PoC trials are where dreams meet reality. The right internal talent is everything.

• 💡 Avoid shortcuts: Consultants and KOLs can’t replace a committed team.

• 🏆 Invest in leadership: A strategic CEO and expert CMO align science and strategy.

• 🌍 Impact lives: A strong team brings therapies to patients.

The biotech world is watching. Investors, regulators, and patients count on your trial.

Build a team to transform lives. Who’s ready to make history? Let’s do this! 🧬

💪 The Unmet Need: Lupus's Relentless Toll

Lupus is a formidable opponent. It’s a chronic autoimmune disease where the body's own immune system attacks healthy tissues, leading to widespread inflammation and organ damage. For my most severe patients, the standard treatments, which broadly suppress the immune system, often fall short. They come with debilitating side effects like increased infections, bone density loss, and metabolic issues. Many patients still suffer from:

• 🙁 Uncontrolled disease flares / Kidney failure that land them back in the hospital.

• 😔 A lifetime of managing side effects that severely impact their quality of life.

• 🚫 A frustrating lack of durable, long-term remission.

✨ My Strong Conviction: Precision Beyond Comparison

This is where next-generation B-cell engagers come in and why I believe they are superior, even to personalized cell therapies, for managing a widespread chronic condition like Lupus.

Think of these engagers as molecular snipers.

• Bispecific B-cell Engagers: These are engineered proteins that act as dual-ended precision tethers. One end latches onto those problematic, antibody-producing B-cells that fuel Lupus inflammation. The other end seizes a specific immune killer cell, such as a T-cell, forcing direct and lethal contact. This allows our immune system to precisely eliminate only the harmful B-cells, leaving beneficial immune cells largely untouched.

• Trispecific B-cell Engagers: These take that precision a step further. They incorporate a third binding site, which can be used to activate the killer immune cell further or even protect it from the disease's "evasion tactics." This creates an even more potent, targeted, and safer attack against the rogue B-cells.

💡 Why I See Them as Superior to Cell Therapy in This Context

While cell therapies (like CAR T-cells) are powerful for certain conditions, I believe B-cell engagers offer critical advantages for the broad Lupus population:

• 💉 Off-the-Shelf Accessibility: As a clinician, the logistics of cell therapy are daunting. It requires collecting a patient's cells, performing complex laboratory modifications, and then reinfusing them. This takes weeks, is incredibly expensive, and limits access. Engagers, however, are readily available biologics. They're manufactured at scale and can be administered immediately, vastly improving patient access and timeliness of treatment.

• 📉 Reduced Manufacturing Complexity & Cost: The intricate, personalized manufacturing of cell therapies drives up their cost. Engagers, as biologic drugs, leverage established, scalable manufacturing processes, leading to potentially lower production costs and more affordable treatments.

• ⏱️ Faster Treatment & Accessibility: When a Lupus patient is experiencing a flare, we need immediate action. Engagers can be given quickly in a clinical setting, providing faster relief compared to the multi-week turnaround for cell therapy. This also means fewer long, arduous journeys for patients who live far from specialized centers.

• 🛡️ Enhanced Controllability & Safety: Unlike living cell therapies that persist indefinitely, engagers are cleared from the body. This may allow for more controlled dosing and the potential for a more favorable safety profile, which is particularly important for chronic conditions.

💖 The Transformative Patient Impact I Envision

For the countless individuals battling Lupus, this innovation holds immense promise:

• 😌 Truly Targeted Therapy: Moving beyond broad immune suppression means fewer debilitating side effects and a better quality of life.

• 📈 Deeper, More Durable Remissions: My hope is for patients to achieve longer periods free from disease activity, reclaiming their lives.

• 🌟 Genuine Hope: This represents a new frontier, offering a path to fundamentally change the course of Lupus rather than just manage its symptoms.

🚀 Strategic Imperative: Why CMOs & CSOs Must Prioritize This

For Chief Scientific Officers (CSOs) and Chief Medical Officers (CMOs) investing in these B-cell engagers is not just a scientific opportunity; it's a strategic imperative for future-proofing healthcare and driving value.

• 💰 Massive Market Opportunity: Lupus affects an estimated 5 million people globally. From my clinical perspective, a significant portion — likely over 1 million patients with moderate to severe disease — are desperately in need of better, safer options. This represents a substantial total addressable market for highly effective, targeted therapies like our B-cell engagers, potentially reaching into the multi-billion-dollar range annually.

• 📈 Commercial Viability & Scalability: The "off-the-shelf" nature of engagers translates directly into superior commercial scalability compared to personalized cell therapies. This means meeting global demand, driving significant revenue, and ensuring the accessibility that healthcare systems need.

• 🔬 Platform Power & Pipeline Acceleration: The underlying technology platform for designing bispecific and trispecific engagers is highly adaptable. Success in Lupus can be leveraged to rapidly develop new therapies for other major autoimmune diseases (e.g., rheumatoid arthritis, multiple sclerosis), creating a robust, high-value pipeline for years to come.

• 👑 Competitive Leadership & IP Advantage: Being at the vanguard of this technology provides a strong competitive moat. Novel multi-specific formats generate invaluable intellectual property, protecting market exclusivity and cementing a leadership position in immunology.

My experience has shown me that true breakthroughs come from addressing the core mechanisms of disease with precision. I firmly believe that bispecific and trispecific B-cell engagers are the breakthrough for Lupus. They offer unprecedented hope for patients, dramatically improving accessibility even for those traveling long distances, and represent a compelling and scalable commercial opportunity that CMOSs and CSOs simply cannot afford to ignore.

The Immune Amnesia Phenomenon

Measles’ most chilling trait is immune amnesia, where the virus wipes out the immune system’s memory. By targeting CD5O lymphocytes, measles suppresses immune function, leaving patients—especially children—vulnerable to secondary infections for up to a year post-recovery. The NEJM article notes that pneumonia, affecting approximately 6 cases per 100 in developed countries, is the leading cause of measles-related hospitalizations. This immune suppression makes measles a formidable adversary, as it undermines defenses against other pathogens. Research into accelerating immune restoration is critical, as immune amnesia extends measles’s impact far beyond its acute phase.

A Highly Contagious Foe

Measles is a highly contagious disease, with a reproductive number (R0) that ranks it among the most infectious diseases. The article stresses that herd immunity requires 95% coverage for both doses of the measles vaccine—a daunting goal. Global coverage for the first dose fell to 86% during the pandemic, the lowest since 2008, and only reached 89% by 2023. With 70 countries below the critical 95% threshold, outbreaks remain a risk. Measles spreads before symptoms, such as Koplik spots or rash, appear, underscoring the delicate balance between virology and public health.

The Vaccine:

A Proven Shield with Challenges The measles vaccine, whether standalone or combined with mumps, rubella, or varicella, is a proven defense with a strong safety record and efficacy across all genotypes. However, the article highlights a key issue: maternal antibodies wane in infants by 2–12 months, increasing susceptibility. This drives the need for research into early vaccination strategies to protect the youngest in high-risk areas. The vaccine’s success depends on timing, access, and overcoming logistical barriers, making it a vital case study in global health equity.

Vitamin A: A Mitigating Ally

The article advocates for vitamin A supplementation as a crucial tool to mitigate measles complications, particularly in individuals with deficiencies, which are common in low- and middle-income countries. While it doesn’t prevent infection, vitamin A reduces the risk of severe outcomes, such as keratitis or keratoconjunctivitis, which affects approximately 30 cases per 100 in developed countries. This simple intervention bridges nutrition and disease management, though more data are needed on its benefits in developed nations where deficiencies are less prevalent.

Clinical Hallmarks and Complications

Measles presents distinct clinical features: Koplik spots on the buccal mucosa signal its onset, followed by a rash spreading from the trunk to the limbs. Conjunctivitis and fever mark its progression, with infectiousness peaking before day 4 post-rash and potential exposure as early as day 23 pre-symptoms. Beyond pneumonia, complications like diarrhea (30 per 100 cases) reveal measles’s multisystem impact, making it a compelling subject for studying viral pathogenesis.

The Vaccination Coverage Crisis

The article reveals a stark reality: 99% of 1500 countries analyzed had MMR coverage below 95% in 2023, fueling outbreaks. The pandemic disrupted campaigns, with low- and middle-income countries hit hardest at 86% coverage. The call for randomized trials on vaccine patches holds promise for simpler delivery methods to enhance coverage, particularly in resource-limited settings. This is an exciting frontier for biotechnology and public health innovation.

Why Measles Matters in 2025

Measles’ ability to exploit immune vulnerabilities, coupled with vaccination challenges, makes it a persistent threat. The NEJM review recommends research into immune restoration, early vaccination, and novel delivery systems, such as vaccine patches. This is a rallying cry for scientists, policymakers, and health advocates to unite for a future free from measles. By leveraging these insights, we can drive innovation and protect communities worldwide.

https://www.nejm.org/doi/full/10.1056/NEJMra2504516

#Measles #Immunology #eswark #drugdevelop

Introduction to CAR-T Therapy

What Is CAR-T Therapy?

CAR-T (Chimeric Antigen Receptor T-cell) therapy is a revolutionary treatment that reprograms your immune system to fight disease. Doctors take T cells (immune cells that act like soldiers) from your blood, modify them in a lab to recognize harmful cells, and then put them back into your body. These upgraded T cells hunt down and destroy the target cells, like a guided missile. The graphic below shows the steps in the autologous (using the patient’s own blood cells) CAR-T

From Cancer to Autoimmune Diseases

CAR-T therapy first gained fame for treating blood cancers, helping some patients achieve complete remission. Now, researchers are using it to tackle autoimmune diseases—conditions where the immune system mistakenly attacks healthy tissues, like in systemic lupus erythematosus (SLE), myasthenia gravis, or systemic sclerosis. The goal is to “reset” the immune system, potentially offering long-term relief without constant medications.

Why This Is Exciting

For people with severe autoimmune diseases who don’t respond to standard drugs, CAR-T could be a lifeline. A single treatment might stop the disease for years, reducing the need for daily pills or infusions. The recent acquisition of Capstan Therapeutics by AbbVie shows that big pharmaceutical companies are betting on this technology, signaling a bright future.

The Competitive Landscape: Who’s Making It Happen?

The field of CAR-T therapy for autoimmune diseases is growing fast, with companies and universities working together to develop new treatments. Here’s a look at the key players, their approaches, and the latest progress.

Emerging Clinical Evidence

A Surge in Research

Research is booming, with over 50 clinical trials worldwide exploring CAR-T for autoimmune diseases. A 2024 study by Zhou et al. in the New England Journal of Medicine showed that 15 patients with lupus, myositis, or systemic sclerosis had major improvements after a single CAR-T treatment. Lupus patients achieved full remission, and no relapses were seen up to two years later.

Diseases and Trials

Here’s a quick overview of the research scope:

Disease Number of Ongoing Trials Systemic Lupus Erythematosus (SLE) ~20 Myasthenia Gravis ~10 Systemic Sclerosis ~8 Idiopathic Inflammatory Myositis ~7 Multiple Sclerosis ~5

This table shows how CAR-T is being tested across a range of autoimmune conditions, with lupus leading the way.

Key Players and Programs

Bristol Myers Squibb (BMS)

BMS, a leader in cancer CAR-T therapies like Breyanzi, is developing CD19 NEX-T, which targets B cells (immune cells that drive many autoimmune diseases). They’re testing it for severe conditions, with results expected in 2025.

Kyverna Therapeutics

Kyverna’s KYV-101 is a CAR-T therapy designed to minimize side effects like immune overreactions. It’s being studied for stiff person syndrome, myasthenia gravis, and lupus nephritis, with plans to seek FDA approval for some conditions by 2025.

CRISPR Therapeutics

Using their gene-editing expertise, CRISPR Therapeutics is working on CTX112, an “off-the-shelf” CAR-T therapy that doesn’t need to be customized for each patient. This could make treatment faster and more accessible, and they’re testing it for various autoimmune diseases.

Cabaletta Bio

Cabaletta’s CABA-201 targets B cells for lupus and related conditions. They’re running trials at places like UC Davis Health to evaluate its effectiveness.

Academic Pioneers

Universities are driving innovation too. The University of Chicago Medicine and Germany’s University of Erlangen-Nuremberg are running early trials on CAR-T therapies for lupus, systemic sclerosis, and myositis, exploring new ways to target the immune system.

Innovative Approaches

Off-the-Shelf CAR-T

Traditional CAR-T uses a patient’s own cells, which takes time to prepare. Allogeneic (off-the-shelf) CAR-T, being developed by companies like Allogene Therapeutics, uses donor cells that can be pre-made, making treatment quicker and potentially cheaper.

New Targets

Most CAR-T therapies target B cells via a marker called CD19, but researchers are exploring other targets like BCMA (on plasma cells) or fibroblast-activated protein. This could help treat more types of autoimmune diseases.

Regulatory T Cells (Tregs)

Instead of destroying harmful cells, CAR-Tregs are designed to calm the immune system. This could be a gentler approach for diseases like multiple sclerosis, where immune balance is key.

Temporary CAR-T

Using mRNA, researchers are creating CAR-T cells that work temporarily and then fade away. This avoids permanent changes to your DNA, potentially reducing risks like secondary cancers.

Challenges Facing CAR-T Therapy

While CAR-T therapy is promising, it faces several hurdles that need to be addressed before it can become a standard treatment. Here’s what’s standing in the way.

Efficacy and Long-Term Outcomes

Will It Last?

Early trials show patients staying symptom-free for years, but we don’t know if this will continue long-term. If B cells return, the disease might come back, so researchers are studying how to make remission last.

Lack of Control Groups

It’s hard to prove CAR-T works better than other treatments because trials often don’t include placebo groups (for ethical reasons, since these diseases can be severe). This makes it tricky to confirm that improvements are due to CAR-T alone.

Safety Concerns

Cytokine Release Syndrome (CRS)

CAR-T can cause CRS, where the immune system overreacts, leading to fever or fatigue. In autoimmune trials, CRS is usually mild and resolves within ~15 days, but it still needs careful monitoring.

Neurotoxicity

Some patients experience brain-related side effects (called ICANS), though these are rare in autoimmune trials. Doctors are working to minimize this risk.

Infection Risks

CAR-T often requires drugs that weaken the immune system temporarily, increasing infection risk. About 25% of trial patients had infections, so vaccinations and follow-up care are crucial.

Long-Term Effects

Some patients lose B cells (25–38%) or antibodies (18–74%) for a long time, which can weaken immunity. There’s also a small risk of late complications, like new cancers, requiring long-term monitoring.

Conditioning Therapy

Many CAR-T treatments need “conditioning” drugs (like chemotherapy) to prepare the body, which adds risks like nausea or hair loss.

Manufacturing and Cost

Complex Process

Making CAR-T cells is complicated. Doctors collect your T cells, modify them in a lab, and return them for infusion. This takes weeks and costs $375,000–$425,000 per treatment in the U.S.

Time Delays

The long manufacturing process can delay treatment, which is a problem for patients with fast-progressing diseases. Off-the-shelf CAR-T could help solve this.

Specialized Centers

CAR-T requires hospitals with trained staff and special equipment, which aren’t available everywhere, limiting access.

Regulatory Hurdles

The FDA requires strict safety plans (called REMS) for CAR-T, adding complexity to getting treatments approved and distributed.

Patient Selection and Disease Heterogeneity

Who’s the Right Fit?

Not all patients benefit from CAR-T. It’s best for those with severe, treatment-resistant diseases and minimal organ damage. Figuring out who qualifies is tough because autoimmune diseases vary widely.

Choosing Targets

Picking the right immune cells to target (like B cells or plasma cells) is challenging. Each disease may need a different approach, and researchers are still learning what works best.

Long-Term Efficacy and Relapse

Immune Reset or Temporary Fix?

We don’t know if CAR-T truly cures autoimmune diseases or just pauses them. If the immune system “reboots” with the same problems, patients might need more treatment.

Comparing to Other Treatments

CAR-T needs to prove it’s better than existing drugs like rituximab (which also targets B cells) or cyclophosphamide. The risks of CAR-T must be worth the benefits.

Additional Therapies

If CAR-T doesn’t fully work, it’s unclear if other immune-suppressing drugs are safe to use afterward, since CAR-T alters the immune system significantly.

Finding Enough Patients

For rare diseases, recruiting enough patients for large trials is hard, slowing down research.

The Path Forward: Overcoming Challenges

Researchers are tackling these hurdles with innovative solutions to make CAR-T safer, cheaper, and more effective.

Improving Safety

• Smart CAR-T Designs: Adding “on/off” switches to CAR-T cells could control side effects.

• Temporary CAR-T: mRNA-based therapies that don’t permanently change DNA could reduce long-term risks.

Streamlining Manufacturing

• Automation: New tech could make CAR-T production faster and less expensive.

• Off-the-Shelf CAR-T: Pre-made therapies could cut wait times and costs.

Expanding Uses

• New Targets: Targeting BCMA, CD138, or other markers could help more diseases.

• Gentler Options: CAR-Tregs might offer a safer way to balance the immune system.

Better Trials

• Larger Studies: More patients in trials will clarify how well CAR-T works.

• Global Data Sharing: International registries are pooling data to speed up progress.

Reducing Costs

• Scalable Solutions: Cheaper manufacturing could make CAR-T more affordable, especially if it saves patients from years of costly drugs.

Why CAR-T Matters

CAR-T therapy could transform how we treat autoimmune diseases, offering hope to patients who’ve run out of options. Early trials show people with lupus and other conditions living symptom-free after one treatment, a huge leap from lifelong medications. With big players like AbbVie investing in companies like Capstan Therapeutics, and universities pushing new ideas, CAR-T could become a standard treatment in the coming years. Overcoming challenges like safety, cost, and access will be key to making this a reality for more people.

Get Involved!

Are you curious about CAR-T therapy or working in healthcare? Share your thoughts in the comments—what do you find exciting or want to learn more about? Let’s connect to discuss how CAR-T could change lives. Subscribe to this newsletter for more beginner-friendly updates on cutting-edge medical advances!

Sources: New England Journal of Medicine (2024), Nature Reviews Rheumatology, BioSpace.

Systemic Lupus Erythematosus (SLE)

SLE is a major focus for cell therapy research, with multiple studies exploring different technologies, including off-the-shelf iPSC-derived cells, dual-targeting CAR-T cells, and allogeneic CAR-NK cells.

OP0032 (Fate Therapeutics): TREATMENT OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS WITH OFF-THE-SHELF IPSC-DERIVED ANTI-CD19 CAR T-CELL THERAPY

• Number of Patients: 3

• Results: In the first three patients treated with FT819, an off-the-shelf iPSC-derived CAR-T product, rapid and deep peripheral B cell depletion was observed. The therapy was well-tolerated, with no reports of severe adverse events, cytokine release syndrome (CRS), or neurotoxicity (ICANS). All patients showed improvements in SLEDAI-2K, PGA, and fatigue scores. The first patient, who had biopsy-proven lupus nephritis, achieved DORIS clinical remission and a low lupus disease activity state by month 6, enabling the discontinuation of corticosteroid therapy.

• Conclusion: Preliminary data indicate that this off-the-shelf CAR T-cell therapy has a favorable safety profile and shows promising initial efficacy in refractory SLE. These findings support its continued evaluation in SLE and other B-cell-mediated autoimmune diseases.

OP0074 (Gracell Biotechnologies/AstraZeneca): PRELIMINARY RESULTS OF CD19/BCMA DUAL-TARGETING FASTCAR-T CELLS GC012F (AZD0120) IN PATIENTS WITH REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS-AN OPEN-LABEL, SINGLE-ARM STUDY

• Number of Patients: 10

• Results: Ten patients with refractory SLE and lupus nephritis received the dual-targeting CAR-T therapy, GC012F. The treatment demonstrated a favorable safety profile, with only Grade 1 or 2 CRS and no high-grade CRS or ICANS reported. Robust CAR-T cell expansion and complete B-cell depletion were observed in all patients, with subsequent B-cell recovery dominated by naïve B cells. Clinically, 9 out of 10 patients achieved DORIS remission by month 9, and all showed a significant reduction in proteinuria. Seven patients were able to stop glucocorticoids completely.

• Conclusion: The dual-targeting CAR-T therapy, GC012F, induced disease remission in refractory SLE patients with an early favorable safety profile. A multicenter phase 1/2 study is now ongoing to further evaluate this therapy.

OP0079 (Novartis): CLINICAL, CELLULAR KINETICS, PHARMACODYNAMICS AND BIOMARKER DATA UP TO 12 MONTHS AFTER YTB323 (RAPCABTAGENE AUTOLEUCEL), A RAPIDLY MANUFACTURED CD19 CAR-T THERAPY, FROM AN OPEN-LABEL, PHASE 1/2 STUDY IN SEVERE REFRACTORY SLE

• Number of Patients: 13

• Results: In 13 patients with severe refractory SLE, treatment with YTB323 was generally well-tolerated, with manageable Grade 1/2 CRS and a single Grade 2 ICANS event that resolved. All patients experienced expected transient cytopenias. In the first three patients with at least 9 months of follow-up, a marked improvement in disease activity was observed (mean SLEDAI-2K decrease of 14.7 points), along with a decrease in anti-dsDNA antibodies and an increase in complement levels. Pharmacodynamic data showed effective B-cell depletion followed by recovery of a predominantly naïve B-cell phenotype.

• Conclusion: Treatment with YTB323 resulted in improved disease activity and effective B-cell depletion. The early clinical data suggest remarkable efficacy and a manageable safety profile, supporting the continued evaluation of this rapidly manufactured CAR-T therapy for severe refractory SLE.

LB0009 (Rui Therapeutics, Nanjing, China): ALLOGENIC CD19 CAR NK CELL THERAPY IN REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS-A CASE SERIES STUDY

• Number of Patients: 24

• Results: In a study of 24 patients with relapsed or refractory SLE, allogeneic CD19 CAR-NK cell therapy was administered. The maximum tolerated dose was not reached. CRS was mild (Grade 1) and occurred in only two patients (8%). No neurotoxicity or other severe adverse events related to the therapy were observed. Among the 12 patients with at least 12 months of follow-up, 66.7% achieved DORIS remission and 75% achieved LLDAS.

• Conclusion: The study supports allogeneic CAR-NK cell therapy as a potent and safe option for treating autoimmune diseases like SLE. This approach may address some of the limitations of autologous CAR-T cell therapy, such as manufacturing time, access, and cost.

Systemic Sclerosis (SSc)

Cell therapies are being explored in SSc, a condition with high unmet need, focusing on safety and impact on skin and organ involvement.

OP0338 (Cabaletta Bio): RESET-SSCTM: CLINICAL TRIAL EVALUATING RESE-CEL (RESECABTAGENE AUTOLEUCEL), A FULLY HUMAN, AUTOLOGOUS 4-1BB ANTI-CD19 CAR T CELL THERAPY IN SYSTEMIC SCLEROSIS

• Number of Patients: 1

• Results: The first patient treated in this trial tolerated the rese-cel infusion well, experiencing a manageable Grade 2 CRS that resolved without tocilizumab, and no ICANS. The patient has maintained a drug-free response through 3 months, with the modified Rodnan skin score (mRSS) improving from 42 to 34. Lung function (FVC and DLCO) also improved. CAR-T cells expanded and were then cleared from the periphery, while B-cells were rapidly depleted from both peripheral blood and lymph node tissue, followed by repopulation with naïve B-cells.

• Conclusion: Initial data from the first SSc patient demonstrates an early clinical response without ongoing immunosuppression and a favorable safety profile. The findings suggest rese-cel has the potential to reset the immune system in SSc.

POS0656 (Bristol Myers Squibb): TOLERABILITY AND EFFICACY OF BMS-986353 (CC-97540), A CD19-DIRECTED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY...FOR SYSTEMIC SCLEROSIS...

• Number of Patients: 5

• Results: Five patients with SSc were treated with BMS-986353. The treatment was generally well-tolerated; one patient experienced a Grade 3 headache related to the therapy. Three patients had Grade 1/2 CRS, and one had Grade 1 ICANS, all of which resolved. No prolonged severe cytopenias or serious infections were reported. In three patients with diffuse cutaneous SSc, the mRSS was reduced by 15, 13, and 0 points at the last follow-up. All patients showed complete B-cell depletion and robust CAR-T cell expansion.

• Conclusion: In patients with severe refractory SSc, BMS-986353 demonstrated a manageable safety profile with brief and reversible CRS/ICANS events. Preliminary data suggest promising efficacy in improving skin scores.

Idiopathic Inflammatory Myopathies (IIM)

Early trial data for CAR-T therapy in IIM shows potential for rapid, drug-free clinical responses.

OP0316 (Cabaletta Bio): RESET-MYOSITISTM: CLINICAL TRIAL EVALUATING RESE-CEL (RESECABTAGENE AUTOLEUCEL), A FULLY HUMAN, AUTOLOGOUS 4-1BB ANTI-CD19 CAR T CELL THERAPY IN IDIOPATHIC INFLAMMATORY MYOPATHIES

• Number of Patients: 3

• Results: The first three patients (two with IMNM, one with DM) tolerated rese-cel well, with no CRS, ICANS, or dose-limiting toxicities observed. One patient with IMNM achieved a moderate Total Improvement Score (TIS) response by Week 24 while remaining off all therapies. The patient with DM showed a rapid and robust major TIS response by Day 29, which was maintained to Week 12. In all three patients, CAR-T cells expanded and peripheral B-cells were rapidly depleted, followed by repopulation with naïve B-cells at 8 weeks in two patients.

• Conclusion: Data from the first IIM patients dosed with rese-cel demonstrate early, immunomodulatory-free clinical responses and a favorable safety profile. These results suggest the potential for rese-cel to reset the immune system and achieve meaningful clinical responses in IIM.

Rheumatic Diseases (Multi-Disease Basket Trial)

A basket trial including patients with SLE, SSc, and IIM demonstrates the broad potential and consistent safety profile of CAR-T therapy across different rheumatic diseases.

POS0062 (Erlangen university lead): SAFETY AND PRELIMINARY EFFICACY OF CD19 CAR T-CELL TREATMENT IN RHEUMATIC DISEASE – DATA FROM THE PHASE I/II CASTLE BASKET STUDY

• Number of Patients: 20

• Results: In a cohort of 20 patients (8 SLE, 8 SSc, 4 IIM), no high-grade (≥3) CRS or any ICANS were observed. Late-onset grade 3/4 neutropenia occurred in 4 SLE patients but resolved. Three severe infections were reported. All seven SLE patients with 6-month follow-up achieved DORIS remission. Both IIM patients achieved a moderate/major ACR response. All six SSc patients showed improvement in skin scores without worsening of lung function. All patients remained off their prior immunosuppressive drugs and glucocorticoids after CAR-T therapy.

• Conclusion: The data from this basket study underline the safety and preliminary efficacy of CD19 CAR T-cell therapy across different severe autoimmune diseases, with no unexpected toxicities and promising clinical responses in all three disease groups.

General / Preclinical Cell Therapy Research

Research into novel CAR-T and cell therapy platforms continues to advance, with a focus on improving safety, manufacturing, and efficacy for broad application in autoimmune diseases.

POS0876 (Kyverna Therapeutics): EFFECT OF ANTI-CD19 CAR T CELL THERAPY IN THE BONE MARROW OF PATIENTS WITH SYSTEMIC AUTOIMMUNE DISEASES

• Number of Patients: 3

• Results: In three patients with severe, treatment-resistant autoimmune diseases, anti-CD19 CAR T-cell therapy was safe and led to stable clinical improvement. Bone marrow biopsies performed after therapy but before peripheral B-cell return showed that B cells, especially CD19+ plasmablasts and plasma cells, were significantly reduced. In one patient evaluated after B-cell reconstitution, the bone marrow B cells were predominantly of a naïve/transitional phenotype, with memory B cells and plasmablasts remaining diminished.

• Conclusion: Anti-CD19 CAR T-cell therapy promotes remission by effectively depleting B-cell populations within primary lymphatic organs like the bone marrow, a key site for long-lived plasma cells.

POS1402 (Fate Therapeutics): A NOVEL PLATFORM... FUNCTIONALLY ENHANCED... CD19 CAR-T THERAPY FOR AUTOIMMUNE DISEASE

• Number of Patients: 1 (in oncology proof-of-concept)

• Results: Preclinical data showed the investigational therapy FT522, an off-the-shelf iPSC-derived CAR-NK cell product, was capable of rapid and potent depletion of B cells from SLE donors in vitro. Early data from a Phase 1 trial in B-cell lymphomas, where FT522 was administered without conditioning chemotherapy, showed the product could persist and function. In a patient with Waldenstrom Macroglobulinemia, this resulted in clinical benefit, including a significant reduction of IgM.

• Conclusion: Preclinical and early oncology clinical data demonstrate that FT522 can persist and function and confer clinical benefit without the need for conditioning chemotherapy. This supports its potential application for B-cell mediated autoimmune diseases, with a Phase 1 trial in this setting planned.

ABS0179 (Universit. Vita Salute San Raffaele, Milan, Italy): UNDERSTANDING CAR-TREG PERSISTENCE AND EXPANSION PROTOCOLS OPTIMIZATION

• Number of Patients: No patients

• Results: Using a humanized mouse model of SLE, this study confirmed that CAR-Treg cells showed an initial expansion followed by contraction, disappearing from peripheral blood after 39 days. The therapy was safe, with no CRS or B-cell aplasia. The study successfully identified an optimized CAR-Treg expansion protocol using a re-stimulation step, which significantly increased cell expansion without compromising phenotype or suppressive function.

• Conclusion: The study successfully tracked CAR-Tregs in vivo and identified an improved method for their expansion, which is critical for optimizing their therapeutic potential and persistence for future clinical applications.

ABS0750 (iCell Gene Therapeutics Inc.): FIRST USE OF NOVEL BCMA AND CD19 NANOBODY-BASED COMPOUND CAR-T THERAPY TO TARGET B-CELLS AND PLASMA CELLS IN PRECLINICAL STUDY OF AUTOIMMUNE DISEASES

• Number of Patients: 1 (compassionate use case)

• Results: A novel BCMA-CD19 compound CAR-T therapy using camelid nanobodies (ncCAR) showed potent killing of target cells in vitro and effective depletion in mouse models. In a compassionate use case, a patient with multiple myeloma and immune thrombocytopenia (ITP) achieved stringent complete remission of their cancer and complete resolution of thrombocytopenia with normalization of platelet counts, demonstrating remarkable safety and efficacy.

• Conclusion: This first-in-human use of ncCAR therapy demonstrated exceptional preclinical and clinical efficacy. The ability of the dual-targeting therapy to resolve ITP validates its potential to deplete the humoral cells that drive autoimmune disease, supporting its investigation for conditions like SLE.

Biological Significance

The 14-3-3 family of proteins is are highly conserved regulatory molecule involved in various cellular processes. The presence of extracellular 14-3-3η and the development of autoantibodies against it point to a specific immune response that may be involved in the pathophysiology of axSpA. Previous work has suggested these autoantibodies could be biomarkers for both inflammation and the potential for radiographic progression in ankylosing spondylitis, making their measurement a rational approach for a diagnostic tool.

Study Design at a Glance

At the EULAR 2025 congress, a study was presented to validate the technical and clinical performance of this new 14-3-3η AAb assay.

• The primary goal was to assess the assay's reliability and its ability to distinguish patients with a confirmed axSpA diagnosis from a control group.

• The clinical validation cohort consisted of 83 patients with axSpA and 57 presumed healthy subjects.

• The researchers utilized Receiver Operator Characteristic (ROC) curve analysis to identify the five most informative peptides and developed a composite scoring model to enhance diagnostic potential.

Assay Performance and Key Results

The study's findings indicate a technically sound and reliable assay.

• Technically, the test demonstrated high precision and an overall accuracy of 96.0% in its measurements. It also showed minimal interference from common substances in the blood.

• Clinically, the assay showed a clear distinction between the axSpA and healthy control groups. When using the composite score, the model produced an Odds Ratio of 8.7 for an axSpA diagnosis.

• A patient with a positive composite score had a Relative Risk of 2.9 for an axSpA diagnosis, while a patient with a negative score had a Relative Risk of just 0.3.

A Clinician's Perspective on the Path Forward

The true diagnostic dilemma in early axSpA often arises in patients who present without the classic hallmarks of disease—they may lack elevated inflammatory markers, definitive radiographic changes, or other systemic features. A highly specific and sensitive blood test would be revolutionary for this very population.

This study successfully demonstrates that the 14-3-3η AAb assay can reliably differentiate diagnosed axSpA patients from healthy individuals, which is a foundational requirement for any new diagnostic test. This work confirms the assay's technical robustness and its potential clinical utility.

However, the critical question for clinicians remains: how does this test perform in the real-world scenario of differentiating early axSpA from the vast spectrum of mechanical and other inflammatory back pain conditions? Answering this question will be the next pivotal step. Future research in cohorts of patients with undifferentiated back pain is necessary to fully establish the role of this biomarker in shortening the diagnostic odyssey for our patients.

Source Abstract:

Marotta A, Liggett J, Maksymowych WP, et al. POS0717: Validation of Anti-14-3-3η (eta) Multiplex Laboratory Developed Test (LDT) for the Diagnosis of Axial Spondyloarthritis (axSpA). Ann Rheum Dis. Published online for EULAR 2025. doi:10.1136/annrheumdis-2025-eular.1600

• The News: A pivotal study simplifies our understanding of CPPD crystals.

• The Shift: Moving from morphological mystery to a single chemical target.

• The Pathways: Three detailed, actionable drug development strategies based on this new evidence.

• The Toolbox: Leveraging Raman spectroscopy as a critical tool in clinical development.

Read more

In a cohort of HS patients presenting with arthralgia, a striking 76% were found to be HLA-B27 positive. This finding alone is a significant signal towards a potential spondyloarthropathy-like phenotype. However, the clinical picture was deceptively benign; a formal swollen joint count was positive in only 12% of these patients, with a median count of zero. This discrepancy highlights the subclinical nature of the condition and the inadequacy of physical examination alone for assessment.

Both serological markers and advanced imaging modalities substantiated objective evidence of inflammation:

• Elevated Inflammatory Markers: The HS cohort exhibited significantly higher median levels of C-reactive protein and erythrocyte sedimentation rate compared to both PsO and control groups, confirming a state of systemic inflammation.

• Musculoskeletal Ultrasound (MSUS): While low-grade, greyscale synovitis was ubiquitous across all groups, the more specific finding of GS-tenosynovitis was detected in 32% of HS patients. This prevalence was comparable to that of the PsO cohort (36%) and substantially higher than in controls (12%). Power Doppler signal, however, was rare across all groups, indicating low-grade vascularization within the inflamed tissue.

• Fluorescence Optical Imaging (FOI): Using the Xiralite method, FOI of the hands revealed significantly higher inflammatory enhancement in HS patients compared to both PsO patients and controls. This points to a distinct and more intense inflammatory signature in the small joints of the hand in the HS population.

The confluence of high HLA-B27 prevalence, elevated inflammatory markers, and definitive imaging evidence of tenosynovitis and synovitis—in the absence of significant clinical swelling—builds a robust case for a true, yet occult, inflammatory arthritis in HS. These findings necessitate a paradigm shift in how we evaluate arthralgia in our patients with HS. For definitive characterization, we must look beyond the physical examination and employ imaging to objectify the underlying pathology.

#HidradenitisSuppurativa #Dermatology #Rheumatology #OccultArthritis #Spondyloarthropathy #HLAB27 #MedicalImaging #DermRheum

The initial excitement came from early animal studies. However, newer and more direct research tells a different story. Here are the facts that challenge the claim:

• Contradictory Evidence: A recent longitudinal study tracked taurine over time in humans, monkeys, and mice. In the animal models, taurine levels did not consistently decline. In fact, they often remained stable or even increased with age. This finding alone works against the central premise.

• Inconsistent Human Data: Data from the Baltimore Longitudinal Study of Aging showed no clear pattern in people. The association between taurine and age was highly inconsistent, varying with factors like sex. A reliable biomarker cannot be this variable.

• Individual Variation i…

Read more

The Rationale: Why Methotrexate Seemed So Plausible

To understand the disappointment, we must first appreciate the hope. Our understanding of OA has shifted dramatically from a simple "wear and tear" disease to a complex disorder involving the entire joint as an organ. A critical component of this new understanding is the role of the synovial membrane, which often becomes inflamed in OA, a condition known as synovitis. This inflammation is not just an innocent bystander; it is a key driver of symptoms and disease progression. An inflamed synovium releases a cocktail of destructive enzymes and pro-inflammatory cytokines that create a vicious cycle, accelerating cartilage breakdown.

Thanks for reading The Journal Club! Subscribe for free to receive new posts and support my work.

This is where methotrexate came into play. MTX has been the anchor drug in the treatment of rheumatoid arthritis for decades, valued for its efficacy and long-term safety profile. Its primary anti-inflammatory mechanism is elegant: it indirectly increases the levels of extracellular adenosine, a natural molecule that powerfully suppresses inflammation by acting on immune cells like macrophages and T-cells.

The logic seemed irrefutable:

1. A subset of knee OA patients has clinically significant synovitis.

2. MTX is a potent, safe, and effective drug for treating synovitis in other diseases.

3. Therefore, giving MTX to OA patients with synovitis should reduce their inflammation and pain.

This created the exciting prospect of not only providing symptomatic relief but also potentially modifying the disease itself, positioning MTX as a candidate Disease-Modifying Osteoarthritis Drug (DMOAD). The stage was set for a definitive clinical trial to prove this concept.

The Definitive Test: A Deep Dive into the Zhu et al. (2024) Trial

The study by Zhu and colleagues in JAMA Internal Medicine was designed to provide a clear answer. It was a large-scale, multicenter, double-blind, placebo-controlled Phase 3 randomized clinical trial—the gold standard of clinical evidence.

The Methods: The researchers recruited 215 participants with symptomatic knee OA. Crucially, to test the hypothesis properly, every single participant had to have MRI-confirmed effusion-synovitis. This wasn't a trial for general OA; it was a trial specifically for the "inflammatory phenotype," the very group MTX was supposed to help. Patients were randomly assigned to receive either oral methotrexate (with the dose increased up to 15 mg per week) or a matching placebo for a full 52 weeks.

The Endpoints: The trial had two co-primary endpoints, designed to assess both symptoms and biology:

1. Pain Reduction: The change in knee pain intensity as measured on a 100 mm Visual Analog Scale (VAS).

2. Inflammation Reduction: The change in the maximal area of effusion-synovitis as measured by MRI.

The Verdict: After a year of treatment, the results were unequivocal and profoundly disappointing. Methotrexate was no better than a placebo.

• For the pain endpoint, the adjusted mean difference between the MTX and placebo groups was a negligible 0.3 mm.

• For the MRI endpoint, the adjusted mean difference in the size of the effusion-synovitis was a statistically insignificant 0.1 cm².

Furthermore, there were no significant differences in any of the secondary outcomes, including WOMAC scores for pain, stiffness, and function. There was one glimmer of a potential signal: a pre-planned subgroup analysis found that among the small number of participants who started the trial with severe baseline pain (a VAS score of 80 or higher), MTX was associated with significantly greater improvements. However, this finding in a small subset does not rescue the overall negative result for the broad population of patients with inflammatory knee OA.

The Post-Mortem: Interrogating the Failure

A negative trial of this quality is not just a failure; it is a trove of invaluable data that forces us to ask tough questions. Why did such a plausible theory fail so definitively? The answers may reshape our approach to the development of OA drugs.

1. The Smoking Gun: A Failure of Proof of Mechanism

The most damning piece of evidence comes from the MRI results. The trial was designed to see if MTX could reduce inflammation, and the imaging clearly showed that it did not. The drug failed to engage its biological target in a meaningful way. This finding is critically important. It suggests that the inflammation present in the OA knee—even when severe enough to be seen on an MRI—is not substantially responsive to the adenosine-mediated anti-inflammatory pathways that MTX relies on. It’s a powerful indication that the synovitis in OA may be a distinct biological entity from the synovitis in RA.

2. A Question of Groundwork: Insufficient Preclinical Studies?

This leads to a more fundamental question. Was the leap from RA to OA made too quickly? The rationale was based almost entirely on MTX’s known effects in RA. It is worth asking whether there was sufficient OA-specific preclinical work to validate that the adenosine pathway was indeed the critical, druggable driver of inflammation in OA models before launching a large-scale Phase 3 trial. This trial’s failure suggests that what works for one type of arthritis cannot be assumed to work for another, even when they share superficial similarities like synovitis.

3. Rethinking the Villain: Is Synovitis the Primary Driver of OA Pain?

The trial presents a fascinating paradox. We know from numerous studies that the presence and severity of synovitis are strongly associated with pain in knee OA. Yet, in a trial where synovitis was present but not reduced by the drug, pain was also not reduced. This may suggest that while synovitis is a contributor, it may not be the primary, direct driver of pain in many individuals. The pain experience in OA is incredibly complex, potentially dominated by other factors like structural damage, bone marrow lesions, or central nervous system sensitization. If the "volume" of the pain signal is coming primarily from these other sources, then turning down the smaller signal from synovitis might not be enough to make a clinical difference.

4. A Problem of Pharmacology: Wrong Dose, Wrong Route?

A crucial gap in the development path is the lack of foundational clinical pharmacology studies for MTX in OA. The doses used in the trial, up to 15 mg weekly, are on the low end of what is often used for RA. The optimal dosing for MTX in knee OA has yet to be defined. Was this dose sufficient to achieve the necessary intracellular concentrations of the drug in OA synovial tissue to exert a meaningful anti-inflammatory effect?. Without formal dose-ranging, PK/PD, and target engagement studies in the specific OA patient population, we are essentially flying blind. It remains a theoretical possibility that a higher dose or a different route of administration (like subcutaneous injection, which has better bioavailability) might have worked, but the evidence to support this does not exist.

Charting a New Path for Osteoarthritis Drug Development

The definitive failure of methotrexate in the general inflammatory knee OA population should not be seen as a tragedy, but as a crucial signpost directing the field toward a more sophisticated future. It teaches us that broad labels like "inflammatory OA" are likely insufficient for effective drug development.

The path forward must be built on the lessons from this trial:

• Precision Over Generalization: We must move beyond "one-size-fits-all" approaches and invest heavily in deep patient phenotyping to identify a responsive subgroup not just by symptoms or a single imaging marker, but by underlying biological mechanisms.

• Validate the Target: We must rigorously validate that a proposed target is not only present but is a critical driver of the disease process in OA before launching large-scale trials.

• Embrace Clinical Pharmacology: Foundational studies on dosing, pharmacokinetics, and pharmacodynamics in the target population are not optional steps to be skipped in the rush to pivotal trials.

The journey to find a DMOAD for osteoarthritis is a marathon, not a sprint. This trial, a "successful failure," provides invaluable data that, while disappointing, ultimately pushes us closer to the finish line by forcing us to be smarter, more precise, and more rigorous in our approach.

#Osteoarthritis #DrugDevelopment #ClinicalTrials #Rheumatology #MedicalResearch

Thanks for reading The Journal Club! Subscribe for free to receive new posts and support my work.

Imatinib, an established drug, had previously shown promise in PAH by targeting key disease pathways. However, its journey was cut short after the large, traditional IMPRES Phase 3 trial, which tested a 400mg daily dose, revealed significant tolerability and safety issues, effectively sidelining it for this indication (see table below). Many would have closed the book. But the innovative spark in its revival, detailed in the Rothman and colleagues' study, was the decision not to discard the drug, but to meticulously re-investigate its fundamental challenge: the therapeutic window. This targeted approach, focusing on identifying a lower, yet still effective, tolerable dose (200mg daily), demonstrates a crucial lesson: initial setbacks, especially dose-related ones, can be overcome with intelligent, focused reassessment —a strategy particularly valuable for biotechs aiming to maximize the potential of their assets.

The true game-changer, however, and the core of its utility as a model for PoC, was the innovative architecture of the Rothman trial. This was not a scaled-down version of a traditional trial; it was a fundamentally different, more agile approach that yielded convincing data from just 17 patients, a stark contrast to IMPRES's 202:

1. Adaptive Design for Lean PoC (The Bayesian CRM): The study employed a Bayesian Continuous Reassessment Model. This statistical method is inherently adaptive, meaning the trial "learns" in real time. The optimal dose for subsequent patients is determined based on accruing safety and tolerability data from those already enrolled. For a PoC study, this innovation is transformative. It allows for efficient dose exploration and identification with a minimal number of patients, drastically reducing timelines and costs while also being more ethical by limiting exposure to ineffective or poorly tolerated doses. This demonstrated that robust dose-finding, a key PoC element, doesn't invariably demand large numbers.

2. Deep Insights from Rich Data (Implanted Sensors): Thirteen patients were equipped with implantable devices providing continuous, daily hemodynamic and activity data. This innovative integration of remote monitoring technology into an early-phase trial yielded a depth of information far exceeding what's typical. Instead of relying on infrequent clinic visits, researchers could observe the nuanced effects of imatinib—its gradual onset, its impact on daily life metrics, and, critically, the drug’s behavior upon withdrawal. This allowed for a robust characterization of the drug's effects from a small cohort, powerfully enhancing the "proof" in the PoC.

3. Strategic Learning & Focus: The trial design explicitly learned from the past. Patients on anticoagulants, a source of safety concerns in IMPRES, were excluded. The primary endpoint was clearly focused on tolerability, directly addressing the major hurdle identified in previous research. This strategic clarity ensured the small trial answered the most pressing questions efficiently.

From this innovative PoC approach, we learned that small, intelligently designed studies can be extraordinarily powerful. They can provide clear, actionable answers, de-risk further development, and offer a more compelling early data package than larger, less focused efforts might. The depth and continuity of data can often outweigh sheer patient numbers in early validation.

For small biotech drug developers, the lessons from imatinib's revival are particularly salient:

• Lean PoC is Achievable: Don't assume that impactful PoC requires massive investment in large patient cohorts. Smart design can deliver convincing results efficiently.

• Adaptive Designs are an Asset: Embrace adaptive methodologies like CRM. They optimize resource allocation (patients, time, capital) and maximize the learning from every data point.

• Technology as a PoC Enhancer: Leverage modern tools like wearables and implantable sensors. They can provide the rich, longitudinal data needed to make a strong case from smaller studies, attracting partnerships and investment.

• Strategic Re-evaluation Unlocks Value: If an asset with a sound scientific rationale has previously stumbled, particularly on dose or tolerability, an innovative, targeted PoC might be the key to unlocking its hidden value.

• Focused Questions, Efficient Answers: Design PoC trials to answer the most critical questions head-on, as the Rothman study did with imatinib's dose-tolerability.

The story of imatinib in PAH, as retold through the lens of the Rothman trial, is far more than an academic exercise. It's a practical demonstration that innovation in trial design can yield profound results with remarkable efficiency. For small biotechs striving to make big impacts with limited resources, this "lean and keen" approach to Proof-of-Concept isn't just an option; it's a strategic imperative for success.

#SmallBiotech #ProofOfConcept #PAH #TrialDesign #DrugDevelopment #Innovation #RareDisease

Hand Osteoarthritis: A Pervasive and Burdensome Condition

Hand osteoarthritis is far from a rare ailment. It's a chronic, disabling disease with a staggering lifetime risk of up to 40%. Globally, osteoarthritis affects over 500 million people, and hand OA is a significant contributor to this burden, accounting for nearly a quarter of all disability-adjusted life years (DALYs) attributed to osteoarthritis – second only to knee OA. The Global Burden of Disease study (1990-2019) highlighted that in 2019 alone, there were 1.53 million new cases of HOA, with an overall prevalence of 159.46 million cases worldwide. This translates to millions of individuals experiencing persistent pain, stiffness, reduced grip strength, and significant difficulties with everyday fine motor tasks. The impact on quality of life is profound, and the economic burden, while not often singled out for HOA specifically, is substantial when considering osteoarthritis as a whole, costing an estimated 1-2.5% of the gross national product in established market economies.

The Elephant in the Joint: Inflammation and Synovitis

For too long, osteoarthritis was dismissed as a simple "wear and tear" disease, a non-inflammatory condition distinct from diseases like rheumatoid arthritis. However, this view is outdated. Strong evidence now clearly indicates that synovial inflammation (synovitis) is not just present but common in osteoarthritis, playing a crucial role in both symptoms and disease progression. Observational studies specifically on hand OA have consistently shown that synovitis is common and is associated with both pain and the worsening of the disease. In most hospital-based hand osteoarthritis (OA) studies, the majority of participants exhibit evidence of synovitis in at least one hand joint when examined by MRI or ultrasound. For instance, in the Nor-Hand study, about two-thirds of participants had synovitis in their interphalangeal joints, and one-third had it in their thumb carpometacarpal joint.

This inflammation isn't a silent bystander. While the total amount of synovitis across the whole hand might only weakly correlate with overall hand pain, synovitis in an individual joint is strongly associated with pain in that specific joint. This link has been confirmed in finger joints. Furthermore, a relationship between synovitis and future disease progression, including the development of erosions, has been demonstrated in multiple hand OA cohorts. This mirrors findings in knee OA, where synovitis is also linked to pain and disease progression. The inflamed synovium in osteoarthritis (OA) joints is characterized by an immune response dominated by the innate immune system, with macrophages playing a crucial role. This inflammatory milieu leads to the release of various mediators, including cytokines like TNF-α, IL-1β, and IL-6, which contribute to pain by sensitizing nociceptors and drive cartilage degradation and bone remodeling. See Table 1

Table 1: Key Inflammatory Mediators and Pathways Implicated in Hand Osteoarthritis Pathogenesis

Proving the Unmet Need: Where Current Treatments Fall Short

Given the prevalence, burden, and the clear role of inflammation, especially synovitis, in driving pain and progression in HOA, one would expect a plethora of effective, targeted treatments. Sadly, this is not the case. Current treatments for HOA are largely symptomatic and fail to address the underlying disease processes, particularly inflammation, in a meaningful or sustained way. This gap firmly establishes HOA as an unmet medical need.

Let's look at the limitations of existing therapies (See Table 2):

Table 2: Limitations of Current Pharmacological Treatments for Hand Osteoarthritis

• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs):

  • Topical NSAIDs: Recommended as a first-line pharmacological treatment by EULAR due to a favorable safety profile. However, supporting evidence is limited, with only one high-quality placebo-controlled trial and conflicting results from studies comparing them to other interventions. Their practicality is also questioned due to the need for frequent hand washing. As of February 2025, no ongoing placebo-controlled randomized controlled trials (RCTs) investigating topical non-steroidal anti-inflammatory drugs (NSAIDs) in hand osteoarthritis (OA) were listed on clinicaltrials.gov, highlighting a significant research gap.

  • Oral NSAIDs: Have demonstrated moderate efficacy in reducing short-term pain. However, their use is limited by potential systemic side effects, especially with long-term use, making them unsuitable as a chronic solution.

• Corticosteroids: These are potent anti-inflammatory drugs.

  • Oral Corticosteroids: The HOPE study demonstrated that 10 mg of prednisolone administered daily significantly reduced pain and improved symptoms in hand osteoarthritis (OA) after six weeks, supporting the hypothesis that synovitis is a key contributor to pain. Treatment even led to a reduction in ultrasound-defined synovial thickening and MRI-defined bone marrow lesions. However, the benefits waned after treatment discontinuation, and long-term systemic side effects make prednisolone unsuitable for chronic use in HOA, though it may be effective for short-term relief.

  • Intra-articular Corticosteroid Injections: Frequently used in clinical practice, but supporting evidence mainly comes from knee OA studies, and its applicability to hand OA is uncertain. EULAR guidelines suggest that they may be considered for painful interphalangeal osteoarthritis (OA), but recommend against routine use. Studies on their use in the first carpometacarpal (thumb base) joint have largely failed to show a significant benefit over saline or local anesthesia, although methodological limitations, including small sample sizes and the absence of a baseline synovitis requirement for inclusion, prevent definitive conclusions.

• Disease-Modifying Anti-Rheumatic Drugs (DMARDs):

  • Synthetic DMARDs (sDMARDs):

    • Hydroxychloroquine: Multiple placebo-controlled RCTs, even in erosive (more inflammatory) hand OA, found no significant benefit, suggesting it's unlikely to have a role in HOA management. The lack of synovitis as an inclusion criterion was a limitation in some earlier studies.

    • Methotrexate (MTX): Results have been more promising but inconsistent. An open-label study first reported symptomatic improvements. One RCT in erosive HOA showed a non-significant trend towards pain relief with 10 mg/week MTX. However, the METHODS trial, using a higher dose (20 mg/week), demonstrated a statistically significant and clinically relevant reduction in pain after six months in patients with synovitis. The Ferrero et al. study also yielded interesting results, with less erosion development and increased repair in MTX-treated patients, although the METHODS trial did not assess structural progression. Neither prednisolone nor methotrexate is currently recommended in international guidelines for HOA, primarily because the key studies supporting their efficacy were published after the most recent updates to the EULAR and ACR guidelines.

  • Biological DMARDs (bDMARDs): Despite many trials focusing on hand OA (evaluating TNF inhibitors, IL-1, IL-6, and GM-CSF inhibitors), these have generally not achieved their primary efficacy endpoints. Consequently, current guidelines do not recommend their use. Some analyses suggest potential disease-modifying effects of TNF inhibitors in swollen joints or possible clinical benefits in per-protocol analyses, indicating that the final word on inhibiting these cytokines may not yet be spoken. The failure of these biologics may be due to OA's clinical heterogeneity and the possibility that the inflammatory mechanisms in OA differ from those in diseases like rheumatoid arthritis, where these drugs are effective.

• Other Anti-Inflammatory Treatments: Apremilast, colchicine, and diacerein have also been tested against a placebo in hand OA without success.

In essence, there are currently no approved disease-modifying osteoarthritis drugs (DMOADs) for hand osteoarthritis. The existing arsenal primarily offers temporary symptomatic relief with limited efficacy, particularly for the inflammatory component, and often comes with concerns about side effects or practicality. There's a persistent gap between our growing mechanistic understanding of HOA and therapeutic success.

The Market and Commercial Opportunity: A Call for Innovation

The overall osteoarthritis market is substantial and growing, projected to expand significantly in the coming years, driven by aging populations and increasing obesity rates. While specific market size figures for hand OA are often subsumed under the general OA market, the "Erosive Hand Osteoarthritis Market" alone was estimated at USD 3.77 billion in 2025 and is projected to reach USD 6.30 billion by 2032, growing at a CAGR of 7.6%. This highlights a significant commercial opportunity.

The limited effectiveness of current treatments for (erosive) hand OA, which only provide symptomatic relief without altering disease progression, is a key driver for this market. There is a clear need and commercial incentive for novel therapies, particularly DMOADs that target specific underlying pathways of the disease, including inflammation and structural damage. Such drugs could be first-in-class for this debilitating condition. The projected 48.6% increase in hand OA cases by 2050 underscores the growing patient population and, consequently, the expanding market for effective treatments.

Call to action

The evidence is clear: synovitis is a common and crucial factor in the pain and progression of hand osteoarthritis. Yet, our current treatments largely fail to effectively target this inflammation. This glaring unmet medical need demands a shift in focus from drug developers. Future clinical trials must prioritize the careful selection of study populations with clear signs of synovitis and possibly MRI evidence of inflammation, employ appropriate treatment durations, and include long-term follow-up to assess potential disease-modifying effects. It's time to move beyond simply managing symptoms and earnestly pursue therapies that can quell the inflammatory fire in hand osteoarthritis, offering real hope for modifying the disease and improving the lives of millions.

The "Valley of Death" (VoD) refers to the critical transitional stage where a drug candidate, having shown promise in in vitro and in vivo preclinical models, enters human clinical trials. It's here, typically during Phase I (safety), Phase II (efficacy and dose-ranging), and early Phase III (larger-scale efficacy and safety), that the highest rates of attrition occur. As one source notes, "The VoD is defined as the transition of a company from pre-clinical stages to human trials, which most efforts do not survive."¹ (Rapid Innovation Group). The chasm signifies a gap not just in funding, but in translational predictability, where promising science fails to translate into tangible clinical benefit for patients.

Consider this stark reality: while estimates vary, the overall probability of success from Phase I to approval can be distressingly low. For instance, one analysis highlighted by the NCBI indicates that overall success rates post-Phase I can be as low as 19% for all investigated projects, with specific therapeutic areas, such as oncology, facing even steeper odds (e.g., a 8% likelihood of overall approval from Phase 1 for neoplasms in one academic study cohort).

The journey from lab bench to bedside is arduous. Consider these sobering average success rates in clinical development:

Preclinical to Phase I: ~50-60% (Initial human safety hurdles)

Phase I to Phase II: ~30-50% (Early efficacy signals/dose finding falters)

Phase II to Phase III: ~30-40% (Insufficient efficacy/safety in target populations)

Phase III to Approval: ~50-60% (Pivotal trial failures)

Data from: "The Current Status of Drug Discovery and Development as Originated in United States Academia," PMC6226120

Why Do So Many Promising Candidates Perish in the Valley?

The reasons for this high failure rate are multifaceted, creating a formidable barrier to delivering treatments:

1. Translational Failures & Preclinical Model Limitations: A primary culprit is the often-poor predictive validity of preclinical models. Animal models, while invaluable, may not accurately replicate the complexity of human diseases or drug responses. As noted by Frontiers in Systems Biology, "The location of the Valley of Death...is evidence that the main problem is...the inability to efficiently translate basic science knowledge obtained from preclinical studies into effective therapies."² This leads to candidates failing to show efficacy or exhibiting unexpected toxicity in humans.

2. Insufficient Understanding of Disease Heterogeneity & Target Engagement: Diseases, particularly complex ones like cancer or neurodegenerative disorders, are not monolithic. A drug target validated in a specific cellular context may not be relevant across diverse patient populations or disease subtypes. Failure to demonstrate clear target engagement and a corresponding biological effect in early clinical studies is a common pitfall.

3. The Funding Chasm: Early-stage clinical development is expensive, and the associated risks are high. Securing adequate, sustained funding to navigate Phase I and II trials, especially for smaller biotechs or academic-led projects, is a significant challenge. This "financial gap" can prematurely terminate promising, albeit high-risk, programs. ResearchGate highlights financial gaps as a primary driver of the VoD.

4. Suboptimal Clinical Trial Design & Execution:

• Poor patient selection or stratification: Enrolling an "all-comers" population when a drug is likely to benefit a specific, molecularly defined subgroup can dilute efficacy signals.

• Inappropriate endpoints: Chosen endpoints may not be sensitive enough, clinically relevant, or capture the true patient benefit.

• Operational complexities, including issues with site selection, patient recruitment, and data quality, can compromise trial integrity. WCG Clinical notes that "Poor study design is the number one reason for trial failure."

5. Regulatory Hurdles & Evolving Standards: Navigating the complex regulatory landscape requires significant expertise and resources. Uncertainty about regulatory expectations, especially for novel modalities or endpoints, can deter investment and slow progress.

6. Lack of Robust Biomarkers: Predictive and pharmacodynamic biomarkers are crucial for identifying responsive patient populations, demonstrating target engagement, and providing early indicators of efficacy. The absence of validated biomarkers significantly increases the risk of failure in later, more expensive phases.

The impact on patients is direct and devastating. Each failure in the valley means delayed access to potentially life-saving or life-improving therapies, continued suffering, and lost hope. As IQVIA points out, "When trials get shut down...patients lose the hope of potentially lifesaving treatments coming to market."

What can be done about this?

While the challenges are immense, we are not without strategies. A multi-pronged, patient-centric approach is essential:

1. Enhancing Translational Science & Preclinical Rigor:

• Improved Models: Investing in more physiologically relevant preclinical models, including humanized mice, patient-derived xenografts (PDXs), organoids, and microphysiological systems ("organs-on-chips"). The NIH's National Center for Advancing Translational Sciences (NCATS) emphasizes that a "major focus of translational science" must be on improving the preclinical to clinical transition.

• Reverse Translation: Feeding clinical observations back into preclinical research to refine models and hypotheses.

2. Embracing Biomarker-Driven Development:

• Early Integration: Prioritizing the discovery, validation, and integration of predictive, prognostic, pharmacodynamic, and safety biomarkers from the earliest stages.

• Patient Stratification: Using validated biomarkers to enrich trial populations for likely responders, increasing the probability of demonstrating efficacy and ensuring the right patients receive the right investigational medicine. This is key to "advancing personalized medicine," as highlighted by research in the European Journal of Public Health.

3. Innovative and Adaptive Clinical Trial Designs:

• Adaptive Trials: Designs that allow for pre-specified modifications based on accumulating data (e.g., sample size re-estimation, arm dropping, population enrichment). The FDA has acknowledged the advantages of such designs for improving statistical efficiency.

• Basket/Umbrella/Platform Trials: Efficiently testing multiple drugs in a single disease or a single drug in multiple diseases/molecular subtypes, often under a master protocol.

4. Fostering Collaboration and Data Sharing:

• Public-Private Partnerships: Encouraging collaboration between academia, industry, regulatory agencies, and patient advocacy groups to share knowledge, resources, and risk.

• Pre-Competitive Data Sharing: Initiatives that allow for the sharing of baseline data, natural history information, and even anonymized failed trial data can inform future development.

5. Strategic Funding and De-Risking Initiatives:

• Catalytic Funding: Increased availability of grants and venture philanthropy for early, high-risk clinical stages. Organizations like the Rainwater Charitable Foundation exemplify how targeted funding can push therapies forward.

• Milestone-Driven Investment: Staging investments based on the achievement of clear translational and clinical milestones.

6. Leveraging AI and Real-World Evidence (RWE):

• AI in Drug Discovery & Development: Utilizing AI for target identification, predicting drug efficacy/toxicity, optimizing trial design, and analyzing complex datasets.

• RWE Integration: Using real-world data to inform trial design, identify unmet needs, and understand long-term effectiveness and safety, potentially supplementing traditional trial data where appropriate.

Cautious Optimism for Patients

The "Valley of Death" in clinical development remains a formidable obstacle. However, by embracing scientific rigor, innovative methodologies, collaborative frameworks, and an unwavering focus on the patient, we can improve the odds. It requires a shift from isolated efforts to an integrated ecosystem dedicated to translating scientific promise into clinical reality.

The ultimate beneficiaries of navigating this valley more effectively are the patients whose lives depend on our ability to deliver safe and effective new treatments. The journey is arduous, but the destination—ameliorating human suffering—is a powerful impetus for continued innovation and perseverance.